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ABSTRACT 
BACKGROUND: Inflammatory cytokines (IL-6, TNF-α) released by adipose tissue in 
obese subjects may enhance the local immune response in the periodontal tissues. It is 
unclear whether the cytokines released by adipose tissue into serum are correlated to 
the amount found in the gingival crevicular fluid (GCF). 
AIM: To investigate the correlation, in obese patients, between the GCF levels of IL-6 
and TNF-α with the levels in serum. 
MATERIALS AND METHODS: 26 obese patients were recruited from obesity clinics 
at Westmead Hospital. Obesity was defined using a body mass index (BMI) ≥30kg/m2. 
Patients with conditions known to affect periodontal tissues, such as uncontrolled 
diabetes (HbA1c >8%) and smoking, were excluded. 
Serum and GCF samples were collected and analysed for IL-6 and TNF-α using 
commercially available ELISA kits. Within each subject GCF was collected from two 
healthy sites (n=26 subjects) and two gingivitis sites, defined by bleeding on probing 
(n=22 subjects). The GCF samples were collected using standardised periopaper strips 
(Proflow). The levels of IL-6 and TNF-α in the GCF were compared and correlated 
with the levels found in serum using Spearman‟s correlation analysis. A Bland-Altman 
analysis was used to determine the level of agreement between serum and GCF 
samples. 
RESULTS: TNF-α was detectable in 64% of serum samples but in only 52% and 36% 
of the GCF samples from healthy and gingivitis sites, respectively. In contrast, IL-6 
was found in all serum but only 73% and 95% of samples taken from healthy and 
gingivitis sites, respectively. There was no significant correlations between the TNF-α 
in serum and GCF samples from healthy (r=0.27, p=0.22) and gingivitis (r=-0.19, 
p=0.40) sites. In contrast, positive correlations were found for IL-6 when the serum 
levels were compared with GCF samples from healthy (r=0.48, p=0.03) and gingivitis 
(r=0.79, p=0.0001) sites. The correlation and agreement was strongest for IL-6 between 
serum and gingivitis GCF samples.  
CONCLUSION: These results suggested a lack of correlation between the level of 
TNF-α in serum and GCF. This might be explained by the number of samples below 
the detection threshold. IL-6 from healthy GCF samples showed a low correlation and 
poor agreement. The high correlation between serum and GCF samples from gingivitis 
sites might indicate that higher serum IL-6 increases the GCF IL-6 in response to 
plaque accumulation. Alternatively, the presence of gingival inflammation might lead 
to higher serum levels of IL-6. Overall, the results suggested that future studies 
examining the relationship between BMI and gingival cytokine levels should also 
examine serum samples. 
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1. INTRODUCTION 
Obesity is recognised as a low-grade inflammatory disease and is associated with a 
variety of co-morbidities (Bray & Bellanger 2006, Pischon et al. 2007). It is a rapidly 
emerging health concern; with 25.6% of Australian men and 24% of women classified 
as obese (ABS 2009). Obesity is defined by a body mass index (BMI) ≥30kg/m2 
(Deurenberg et al. 1998). BMI is used to stratify the risk for obesity-related illness 
(Rimm et al. 1995). Although obesity is associated with many diseases, the underlying 
mechanism of these associations remains unclear.  
 
Recent debate within the periodontal literature focuses on the weak association between 
periodontitis and cardiovascular disease (DeStefano et al. 1993, Persson et al. 2003, 
Tonetti 2009). The supporting evidence is predominantly cross-sectional and may be 
confounded by the presence of obesity. Obesity is a key risk factor for cardiovascular 
disease (Rimm et al. 1995) and has recently been associated with periodontitis (Al-
Zahrani et al. 2003, Dalla Vecchia et al. 2005, Saito et al. 1998, Ylöstalo et al. 2008). 
The mechanisms explaining this relationship are currently unknown but could be due to 
common risk factors. Therefore, it is important to identify the biological processes 
which connect periodontitis and systemic disease. This will enable future studies to 
adequately control for confounding factors and to investigate common risk factors. 
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2. REVIEW OF THE LITERATURE 
2.1 OBESITY  
2.1.1 Definition and Measurement 
The discovery that obesity is characterised by low-grade systemic inflammation 
(Bastard et al. 2000, Yudkin et al. 1999) has led to revision of the pathological 
processes involved in obesity related illness (Cancello & Clement 2006). Adipose 
tissue is no longer believed to be an inert storage centre for excess lipids (Trayhurn & 
Beattie 2001). An obese rodent model was used to show that TNF-α was elevated 
locally and systemically (Hotamisligil et al. 1993). This study established the role of 
adipose tissue as an endocrine organ. These secretions are cytokines; termed adipokines 
and are thought to play a key role in linking obesity with a variety of systemic diseases. 
 
The term overweight refers to an excess of body weight, whereas obesity refers to an 
excess of fat. Direct measures of body fat are not available clinically. For this reason, 
obesity is assessed by anthropometrics which indirectly estimate body fat (Flodmark et 
al. 2004). The role of anthropometric measurements in the identification, diagnosis and 
treatment of obesity are discussed in the National Institute of Health evidence-based 
statement (2000). 
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Body fat can be estimated in a variety of ways, however, BMI is the most widely used. 
BMI is calculated by the formula weight (kilogram)/height
2
 (metres). A high value 
usually indicates excessive body fat and is associated with an increase in weight-related 
health risks and mortality (Han et al. 2006). Because of its simplicity, BMI categories 
(shown in Table 1) have been used by the World Health Organisation (WHO) to 
classify body fatness (WHO 2004). 
 
Table 1. Classification of body fatness based on BMI 
according to the WHO. 
BMI Classification 
<18.5 Underweight 
18.5-24.9 Healthy 
25-29.9 Overweight 
30-39.9 Obese 
≥ 40 Morbidly Obese 
 
The validity of the BMI has been extensively investigated and the major limitation is 
the tendency to over-estimate body fat in people with unusually large muscle mass, 
such as trained athletes or body builders (Deurenberg et al. 1999). Moreover, the cut-
offs displayed in Table 1 may not apply to ethnic groups other than Caucasians as the 
relationship between percent body fat and BMI differs among ethnic groups 
(Deurenberg et al. 1998, Razak et al. 2007). Amongst Southern Asians, the level of risk 
for developing co-morbidities is reached at a much lower BMI. In contrast, 
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African-American populations require higher BMI values compared with Caucasians to 
reach the same level of risk (Razak et al. 2007).  
 
Waist circumference (WC) and waist-to-hip ratio (WHR) have also been used to 
measure body fat distribution. Of particular relevance, abdominal fat is associated with 
greater health risks than peripheral fat (Donahue et al. 1987, Ducimetiere & Richard 
1989, Higgins et al. 1988). Furthermore, increased abdominal fat was shown to be an 
independent risk predictor even when BMI is not markedly elevated (Lemieux et al. 
1996). WHR was previously used in many epidemiological studies to estimate 
abdominal fat, however, WC provides a better estimate (Pouliot et al. 1994).  
 
WC is measured in centimetres and the correct position for its measurement is midway 
between the lowest rib and the uppermost border of the iliac crest. The tape should be 
placed around the abdomen at the level of this midway point. Subjects carry a higher 
risk of obesity related complications (e.g. cardiovascular disease) when their WC is 
>102cm in Men and >88cm in Women (Balkau et al. 2007).  
 
Overall, BMI is easy to measure, reliable and highly correlated with the percentage of 
body fat and body fat mass (Deurenberg et al. 1991, Gray & Fujioka 1991). In contrast, 
WC reflects abdominal adiposity. Therefore, BMI is most commonly used as a 
screening tool to estimate total body fat. 
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2.1.2 Prevalence 
The prevalence of obesity is increasing around the world. This trend has prompted the 
WHO to describe the increase as a global epidemic (WHO 2004). In Australia, the most 
recent information on obesity prevalence was derived from the self-reported height and 
weight information from the National Health Survey (ABS 2009). This study estimated 
that 2.5 million Australian adults are obese (BMI≥30). Fig. 1 displays the prevalence of 
obesity in Australians by age category and sex. This chart shows that the prevalence 
increases up to the age group of 55-64 and thereafter, falls (Cameron et al. 2003).  
Fig. 1. Prevalence of obesity amongst Australian adults (Cameron et al. 2003) 
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Over the last 25 years, the prevalence of obesity in Australia and around the world is 
increasing (WHO 2004). The prevalence of obesity is now 2.5 times higher than in 
1980 (Cameron et al. 2003). This clearly represents a global health crisis, with 
increasing numbers of people requiring treatment for obesity related conditions. 
 
2.1.3 Obesity and Morbidity 
It is well known that obesity is associated with increased morbidity and mortality. In 
addition to the increased risk of mortality, consequences of obesity include: 
cardiovascular disease, musculo-skeletal disorders, Type 2 diabetes mellitus and some 
cancers. Wannamethe et al. (2005) and Bray and Bellanger (2006) have published 
comprehensive reviews on the morbidity associated with obesity. As an example, the 
relationship between obesity, hypertension and cardiovascular disease is highlighted 
below. The risk of hypertension is five times higher amongst obese individuals 
compared to those with a normal BMI (Wolf et al. 1997). Amongst men ≤65 years old, 
obesity (as assessed with BMI) is a strong risk factor for coronary heart disease with a 
relative risk of 3.44 (95% CI 1.67-7.09) after adjustment for other coronary risk factors 
(Rimm et al. 1995).  
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2.2 OBESITY AS A PRO-INFLAMMATORY STATE 
2.2.1 Adipose tissue 
Adipose tissue is a type of connective tissue in which adipose cells (i.e. adipocytes) 
predominate. These cells are found in clusters or in isolation within the connective 
tissue. Most of these cells are present in large aggregates and thus, they are the major 
constituent of the adipose tissue throughout the body. Two types of adipose tissue exist, 
unilocular (common or yellow) and multilocular (brown). Unilocular adipose tissue is 
composed of cells that contain one large central droplet of yellow fat in their cytoplasm. 
Multilocular adipose tissue is composed of cells that contain numerous lipid droplets 
and abundant brown mitochondria which is primarily involved in thermogenesis in the 
neonate (Junqueira & Carneiro 2005). Adults have minimal multilocular adipose tissue 
and therefore, all discussion of adipose tissue and adipocytes in this review refers to 
unilocular adipose tissue and its adipocytes. 
 
Non-fat cells are also present within the adipose tissue. Collectively, these non-fat cells 
are known as the vascular stroma fraction. Communication between these cells occurs 
through the release of adipokines. The local production of adipokines regulates adipose 
tissue homeostasis. The discovery that adipose tissue can function as an endocrine 
organ has been attributed to the classic research of Hotamisigil et al. (1993). This group 
showed that TNF-α was released locally within the adipose tissue as well as 
systemically into the circulation. This initiated further research on the role of cytokines 
in obesity related disease. 
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Discrepancies exist between the cytokines which are abundant in adipose tissue 
compared with those found in the circulation. This may be explained by the release of 
soluble receptors. If the soluble receptor of an adipokine is present, binding may 
deactivate the adipokine to limit its distant effect. This was thought to occur to TNF-α 
following its secretion by adipose tissue and might explain why serum TNF-α levels 
have inconsistent correlations with BMI (Khaodhiar et al. 2004, Park et al. 2005).  
 
2.2.2 Adipocytes 
The homeostatic function of adipokines would suggest that their release is dependent 
on the size of the adipocyte cell. Recently, an association was found between adipocyte 
size and the levels of TNF-α, IL-6 and CRP in serum (Bahceci et al. 2007). The close 
relationship between these adipokines has prompted the suggestion that TNF-α actually 
stimulates the secretion of IL-6, which in-turn induces hepatic CRP production (Bullo 
et al. 2003). 
 
The local autocrine and paracrine actions of adipokines appear sufficient to influence 
adipocyte function (Bastard et al. 2002). Adipose tissue, but no other tissue, is 
stimulated by insulin to express mRNA for IL-6 and TNF-α. This supports the local 
function of these cytokines in adipose tissue (Krogh-Madsen et al. 2004). 
Consequently, increased IL-6 production by human adipose cells may have a role in the 
development of the insulin-resistant state observed in obesity. Similarly, TNF-α has 
been linked to insulin resistance (Kern et al. 2001). On a local level, TNF-α appears to 
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play a central role in the function of adipose tissue. TNF-α stimulates the release of 
leptin from adipocytes and in-turn, suppresses appetite and promotes thermogenesis. 
Apart from this effect in adipose tissue, TNF-α also stimulates IL-6 production within 
other tissues (Berg et al. 1994, Heinrich et al. 1990). 
 
Berg et al. (1994) postulated that the effect of TNF-α on adipocyte cells may be related 
to the reduced expression of lipoprotein lipase enzyme. This may enhance the 
sensitivity of the adipocytes to lipolysis. Secondly, the reduced expression of GLUT-4 
and insulin receptor substrate- 1 (IRS-1) could reduce insulin‟s ability to promote re-
esterification (McCarty 1999). This would contribute to the down regulation of insulin-
stimulated glucose uptake (Coppack 2001) and reduce the amount of energy stored as 
glucose within the adipocyte.  
 
2.2.3 Macrophage infiltration 
An excessive presence of macrophages in a tissue sample implies the presence of 
chronic inflammation. Normally, macrophage infiltration of adipose tissue occupies up 
to 10% of the cell types present, however, diet-induced weight gain can increase this to 
60% (Weisberg et al. 2003). The mechanism leading to macrophage infiltration of 
adipose tissue is poorly understood but may result from an increase in chemokine 
signalling, or alternatively following adipocyte necrosis. Adipocyte necrosis could 
occur due to the critical mass effect, i.e. rapid tissue expansion followed by a 
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subsequent lack of nutrients (Attie & Scherer 2009). Conversely, weight loss reduces 
the macrophage content of adipose tissue (Cancello et al. 2005). 
 
Inflammatory signals arising from adipocytes induce a dramatic increase in IL-6 and 
TNF-α secretion by otherwise unstimulated cultured macrophages (Berg et al. 2004). 
This highlights the immunological relationship between adipocytes, macrophages and 
the inflammatory mediators which combine to express a pro-inflammatory state. 
 
2.2.4 Cytokine release 
Many cytokines are released by adipose tissue, however, few have been investigated in 
the periodontal literature. Those that are released by adipose tissue and related to 
periodontal disease are discussed below. 
 
TNF-α 
The prevention of adipocyte hypertrophy partially explains the role of TNF-α within the 
adipose tissue. Adipocytes which were removed during liposuction procedures were 
shown to produce TNF-α locally. The secretion of TNF-α also correlated with the BMI 
of the subjects (Fain et al. 2004a). These results suggested that the roles of TNF-α was 
to minimise weight gain. Most of the TNF-α was released by the macrophages trapped 
within the adipose tissue. It is now accepted that much of the TNF-α and IL-6 are 
released by the vascular stroma fraction (Fain et al. 2004a). 
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Cytokines are released at different levels from various fat stores. TNF-α release into the 
systemic circulation by subcutaneous adipose tissue is limited in contrast to other fat 
sources (Mohamed-Ali et al. 1997). Furthermore, TNF-α has been shown to be poorly 
correlated with various measures of adiposity (e.g. BMI) and this is consistent within 
various gender and ethnic groups (Khaodhiar et al. 2004, Park et al. 2005). It is thought 
that TNF-α exhibits local and regional effects; however, its systemic release is limited. 
The released TNF-α may also be bound by its soluble receptor (Mohamed-Ali et al. 
1997). 
 
Chronic exposure to raised TNF-α levels in serum are associated with reduced insulin 
sensitivity which can lead to the development of diabetes (Hotamisligil et al. 1993). 
TNF-α is suggested to cause phosphorylation of the IRS-1 which subsequently results 
in insulin resistance. Reversing this effect, through the administration of soluble 
receptors (to bind the TNF-α), showed promise in animals but not in human trials 
(Ruan & Lodish 2003). Alternative mechanisms explaining insulin resistance include 
altered gene expression within adipose tissue and the liver. For example, adipocyte 
gene expression for adiponectin and IL-6 may be altered. TNF-α can suppress the genes 
involved in glucose uptake and impairment of insulin signalling (Kershaw & Flier 
2004). Due to the limited release of TNF-α into the serum, its predominant influence on 
adipose tissue secretions is through a paracrine mechanism. 
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IL-6 
The IL-6 cytokine and its soluble receptor are released from adipose tissue. Secretion of 
IL-6 is greatest from visceral fat stores with serum levels positively correlated to 
impaired glucose tolerance, insulin resistance and obesity. In experimental models, the 
administration of IL-6 leads to hyperlipidaemia, hyperglycaemia and insulin resistance. 
This occurs through alterations of the insulin receptor (Fernandez-Real & Ricart 2003). 
IL-6 decreases adiponectin secretion and inhibits adipogenesis. These actions, along 
with the other peripheral effects of IL-6, are thought to contribute to obesity and insulin 
resistance (Kershaw & Flier 2004).  
 
Animal studies examining the IL-6 gene suggest that the effect of IL-6 differs between 
the periphery and the central nervous system. Centrally, the IL-6 levels are negatively 
associated with fat mass. Thus, they appear to prevent the deleterious effects of raised 
levels of IL-6 through increased energy expenditure and inhibition of feeding 
(Wallenius et al. 2002). This action supports the role of IL-6 as a central paracrine 
hormone which prevents additional fat accumulation. 
 
The IL-6 cytokine arises from many sources including adipose tissue, fibroblasts, 
endothelial cells and monocytes. It induces the liver to produce CRP, thus, the levels of 
both IL-6 and CRP are well correlated (Bastard et al. 1999, Maachi et al. 2004). The 
level of IL-6 is also known to correlate with increasing BMI (Khaodhiar et al. 2004). 
These findings are important because CRP has been shown to represent an important 
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cardiovascular risk marker (Ridker 2003). IL-6 may also contribute to the secretion of 
hepatic triglycerides (very low density lipoprotein) and has been implicated in insulin 
resistance (Bastard et al. 2002), however, these mechanisms are not clear (Antuna-
Puente et al. 2008). More recently, it was suggested that IL-6 played a role in 
stimulating lipolysis in white adipose tissue second to its release from muscle tissue 
(Pedersen et al. 2004). Although IL-6 is strongly implicated as having a causal role in 
the development of obesity and insulin resistance, some studies reported the opposite 
effect. The effect of IL-6 on different tissues may be responsible for this variability. In 
some tissues, IL-6 may be considered a homeostatic mechanism to decrease the size of 
adipose cells. 
 
Adiponectin 
Adiponectin is expressed by adipocytes and circulates in the blood. The expression 
within adipose tissue is higher in subcutaneous, in contrast to, a visceral location (Fain 
et al. 2004b). Receptors for adiponectin have been found in muscle tissue and the liver. 
There is a strong inverse relationship between serum levels of adiponectin, insulin 
resistance and the existence of a pro-inflammatory state (Chandran et al. 2003, Diez & 
Iglesias 2003). In non-human primates, the onset of obesity and insulin resistance is 
coupled with a decrease in plasma adiponectin (Hotta et al. 2001). Conversely, the 
levels increase with improved insulin sensitivity or weight loss.  
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The metabolic effects of adiponectin include enhancement of insulin sensitivity, 
reduced hepatic glucose output and decreased endothelial cell adhesion molecule 
expression. Adiponectin also restricts the conversion of macrophages to foam cells. 
These actions attempt to counteract the problems associated with diabetes, 
atherogenesis and inflammation (Kershaw & Flier 2004). An in vitro study using fresh 
biopsy samples reported that the expression of adiponectin mRNA was reduced due to 
the actions of TNF-α and IL-6 (Bruun et al. 2003). Serum samples from obese women 
demonstrated that low levels of adiponectin was associated with higher levels of CRP 
and IL-6 (Engeli et al. 2003). Taken together, these studies suggested that adiponectin 
is important in maintaining a healthy body weight. 
 
Leptin 
Leptin is a circulating adipokine which is known to communicate metabolic 
information to the central nervous system (Coleman 1973). The release of leptin by 
adipocytes increases with adipose tissue mass. Most leptin secretion originates from 
subcutaneous fat rather than visceral sources (Kershaw & Flier 2004). Leptin secretion 
is enhanced by TNF-α (amongst many others) and its main role is to signal energy 
sufficiency rather than excess. This interaction may be possible because the TNF-α 
receptor is homologous to the leptin rector. Leptin levels decrease following weight 
loss and caloric restriction (Forsythe et al. 2008). While leptin-deficient obese mice 
have low levels of leptin, humans display increasing levels. This indicates a degree of 
leptin resistance and is poorly understood. Furthermore, the administration of 
exogenous leptin does not resolve weight gain (Bjorbaek & Kahn 2004).  
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Of periodontal significance, gingival biopsies contained greater leptin levels in shallow 
compared with deep pockets (Johnson & Serio 2001). Similarly smokers had lower 
levels of leptin in gingival crevicular fluid (GCF) (Bozkurt et al. 2006). Collectively, 
these studies appeared to suggest that Leptin may be protective or anti-inflammatory, 
although further studies are required.  
 
PAI-1 
Plasminogen activator inhibitor (PAI)-1 is an inhibitor of fibrinolysis although it also 
plays a role in angiogenesis and atherogenesis. PAI-I levels are elevated in obesity and 
insulin resistance (Fain et al. 2004b). Conversely, PAI-1 is reduced following weight 
loss and with various treatments that result in improved insulin sensitivity (Hanusch-
Enserer et al. 2004). Secretion is greatest from visceral adipose tissue but is also 
released by hepatocytes and endothelial cells (Alessi et al. 1997). However, recent 
studies suggested that its release from adipose tissue was minimal (Fain et al. 2004b). 
Elevated circulating PAI-1 is considered to increase cardiovascular risk because of 
decreased fibrinolytic capacity (Juhan-Vague et al. 1991).  
 
Gene knockout studies in mice have revealed that elimination of PAI-1 leads to reduced 
weight gain and increased energy expenditure through improved glucose and insulin 
metabolism. Apart from the possible link between obesity and insulin resistance, PAI-1 
may also promote cardiovascular complications. More recently, serum PAI-1 was 
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found to be elevated in periodontitis subjects (Bizzarro et al. 2007) thus, inferring the 
need to treat periodontitis to reduce cardiovascular risk. 
 
Resistin 
Resistin is predominantly expressed in visceral adipose tissue and displays significant 
effects on insulin-stimulated glucose uptake (Steppan et al. 2001). The relationship 
between resistin, adiposity and insulin resistance is unclear (Banerjee & Lazar 2003). It 
has been positively associated with periodontitis in Japanese women (Furugen et al. 
2008, Saito et al. 2008), however, further research is needed to clarify its periodontal 
significance. 
 
2.2.5 Conditions influencing cytokine levels 
Hypoglycaemia 
Apart from the influence of obesity on the serum levels of IL-6 and TNF-α, the effect 
of hyperglycaemia should be considered. In vitro stimulation of human monocytes with 
high doses of glucose resulted in an increase of these cytokines (Morohoshi et al. 
1996). This increase seems to occur in individuals with either impaired or normal 
glucose tolerance (Esposito et al. 2002). With chronic hyperglycaemia the advanced 
glycation end-products contribute to cytokine gene up-regulation. This increases the 
production of pro-inflammatory cytokines (Schmidt et al. 2001). 
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Menopause 
Menopause is associated with weight gain (Astrup 1999) and thus, the effect of 
menopause on serum adipokines has been investigated (Hong et al. 2007). In healthy 
post-menopausal women (i.e. oestrogen deficient), the level of TNF-α was increased 
while leptin was decreased when compared with healthy pre-menopausal subjects. The 
concentration of leptin in post-menopausal women increases with obesity and this, in 
turn, leads to insulin resistance. Therefore, the hormone levels should be considered in 
studies comparing the concentrations of adipokines between subject groups.  
 
Insulin resistance 
In healthy subjects, insulin binds to the IRS which allows glucose uptake and 
suppression of gluconeogenesis. With insulin resistance, receptor sensitivity is 
decreased and glucose uptake is impaired. This also leads to raised levels of circulating 
free fatty acid and increased ectopic fat accumulation. The consequence of insulin 
resistance includes reduced glucose uptake in skeletal muscle and elevated glucose 
production in the liver. If the increased blood glucose is coupled with impaired insulin 
secretion, Type 2 diabetes mellitus will develop. Therefore, fasting glucose levels or 
glucose tolerance tests are used to assess both impaired glucose tolerance as well as the 
onset of Type 2 diabetes mellitus. The complex relationship between obesity, its 
pro-inflammatory state and insulin resistance needs to be considered when developing 
prevention strategies to decrease the morbidity associated with Type 2 diabetes 
mellitus.  
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Adipocyte function is important for insulin sensitivity. The macrophage infiltrate 
present in adipose tissue contributes to reduced insulin sensitivity through its associated 
cytokine release. IL-6 blocks IRS-mediated insulin signalling in liver and muscle tissue 
to cause insulin resistance (Weigert et al. 2006). Similarly, TNF-α influences the 
negative feedback mechanism and leads to defective signalling. In contrast to these 
cytokines, anti-inflammatory mediators can exert insulin sensitising effects (see Zeyda 
and Stulnig (2009) for review).  
 
Over-nutrition 
Over-nutrition can lead to endoplasmic reticulum stress in which a stress response is 
activated and inflammatory cytokines are released. This process predominately occurs 
in the liver and within adipose tissue due to excess lipid accumulation and disturbed 
energy metabolism (Ozcan et al. 2004). The presence of endoplasmic reticulum stress 
in adipose tissue has been shown to down-regulate GLUT-4 receptors to promote 
insulin resistance (Miller et al. 2007). 
 
2.2.6 Correlation with BMI 
Khaodiar et al. (2004) examined the correlation between BMI and serum levels of IL-6, 
TNF-α and CRP. The authors discovered that while TNF-α was raised in obese subjects 
(BMI≥30), it was not correlated with BMI. In contrast, a significant correlation was 
found between IL-6 and CRP with BMI. This supports the suggestion that IL-6 is 
secreted in an endocrine manner where the level increases in parallel to increasing fat 
20 
 
mass (Khaodhiar et al. 2004). This increase in IL-6 will then stimulate production of 
CRP from the liver and explains their close association (Berg & Scherer 2005). 
 
Studies have shown that weight loss can reduce the levels of CRP, IL-6, TNF-α, soluble 
TNF-α receptors and other cytokines (Bastard et al. 2000, Heilbronn et al. 2001, 
Nicoletti et al. 2003). The results appear consistent regardless of whether weight loss 
was achieved following surgery or with a controlled diet and exercise.  
 
Park et al. (2005) examined obese Korean subjects and showed that serum levels of 
TNF-α, IL-6 and CRP were correlated with BMI, weight, WHR, WC and hip 
circumference. The strongest correlations occurred with IL-6 and CRP. It has also been 
observed that normotensive obese women exhibit a correlation between 
echocardiogram abnormalities and the levels of serum pro-inflammatory cytokines 
(Malavazos et al. 2007). Collectively, this suggests that associations between a number 
of systemic diseases will be confounded by the presence of obesity. 
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2.3. INFLAMMATION 
2.3.1 Definition 
Inflammation was first defined by Celsus in the first century AD as „redness and 
swelling with heat and pain‟ (Rocha e Silva 1994). Redness, swelling, heat and pain 
represent the clinical signs of inflammation. On a cellular level, inflammation is a 
protective response to cell injury serving to destroy, dilute or wall off an injurious 
agent. Inflammation is central to the induction of tissue repair and occurs in 
vascularised connective tissue. Damaged tissue is replaced through a regenerative 
process, or alternatively, can result in the formation of fibroblastic scar tissue (Kumar et 
al. 2005).  
 
Inflammation is commonly divided into acute and chronic phases with chronic 
inflammation being the most relevant to obesity and periodontitis. Whilst inflammation 
is essential for elimination of noxious stimuli and tissue repair; aberrant inflammatory 
responses can result in disease. Examples of this include atherosclerosis, systemic lupus 
erythematosus, tuberculosis and rheumatoid arthritis. More recently, the underlying 
pathology of diabetes (Pradhan et al. 2001) and obesity (Hotamisligil et al. 1995) have 
been thought to have an inflammatory basis. 
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2.3.2 Acute Inflammation 
Acute inflammation is a rapid response to an injurious agent that serves to deliver 
mediators of the host defence, leukocytes and plasma proteins to the site of injury. 
Acute inflammation has three major components: alterations in vascular calibre, 
leakage of plasma proteins and leukocyte migration. Their subsequent activation aims 
to eliminate the offending agent (Kumar et al. 2005). 
 
The pathological course following an injurious agent is mediated through the release of 
soluble chemical factors known as cytokines. Cytokines regulate the activation of the 
resident cells (such as fibroblasts, endothelial cells, tissue macrophages and mast cells) 
and the newly recruited inflammatory cells (such as monocytes, lymphocytes, 
neutrophils, and eosinophils). These mediators participate in the systemic response to 
inflammation (e.g. fever, hypotension, synthesis of acute phase proteins and 
leukocytosis). The key cytokines with a role in acute inflammatory reactions are: IL-1, 
TNF-α, IL-6, IL-11, IL-8, Granulocyte colony-stimulating factor (G-CSF), and 
Granulocyte macrophage colony-stimulating factor (GMCSF) (Feghali & Wright 
1997). Once released, these factors may act in combination with other chemical 
mediators to amplify the inflammatory response. The inflammatory response is 
terminated following the removal of the noxious agent or by inactivation of the 
chemical mediators. 
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2.3.3 Chronic Inflammation 
Chronic inflammation is considered to be inflammation of prolonged duration (weeks 
or months). This occurs if the stimulus is not removed. With chronic inflammation, 
tissue destruction and attempts at repair are proceeding simultaneously. The hallmark 
of chronic inflammation is the presence of macrophages. In addition, lymphocyte 
accumulation, blood vessel proliferation, tissue fibrosis and necrosis are seen in chronic 
inflammation (Kumar et al. 2005). 
 
During chronic inflammation, cytokine interactions promote monocyte chemotaxis 
towards the site of inflammation. Subsequently, macrophage activating factors such as 
INF-γ, MCP-1 and other molecules activate the macrophages while migration inhibition 
factors, such as GM-CSF and INF- γ, retain them at the inflammatory site. The 
macrophages contribute to the inflammatory process by chronically emitting low levels 
of IL-1 and TNF-α (Feghali & Wright 1997). IL-6 is also secreted by macrophages and 
participates in the humoral response during chronic inflammation. The presence of 
these factors can modulate the local immune response and therefore, it is possible that 
an exogenous source of cytokines may amplify the process. 
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2.3.4 C-Reactive Protein 
CRP is an acute phase protein released by the liver. It is largely synthesised by 
hepatocytes and its production is influenced by pro-inflammatory cytokines (Du Clos 
2000, Jaye & Waites 1997). CRP is used as an inflammatory marker because its 
production begins within 4-6 hours of an inflammatory process and continues to rise 
until it plateaus after 36-50 hours (Kushner & Feldmann 1978). This plateau is due to 
its stable half life. A raised CRP can be seen in patients with chronic infections or 
inflammatory disorders. It has been used as a marker of systemic inflammation. Raised 
serum CRP values are predictors of risk for certain diseases.  
 
The risk of future cardiovascular events is associated with raised CRP levels. A relative 
risk of 2.9 has been reported (Ridker et al. 1997). Thus, it appears plausible that any 
condition resulting in increased CRP production could potentially increase the risk for 
cardiovascular events. This simplistic view requires clarification. It may be that the 
inflammatory mediators concurrently raised with CRP are the cause of the increased 
risk not the CRP itself. The usefulness of this marker is also complicated by the higher 
values seen with the African-American race, female sex, with increased BMI and in the 
presence of radiographic evidence of osteoarthritis (Kraus et al. 2007). Interestingly, 
Kraus et al. (2007) found that 61% of the 183 subjects without cardiovascular disease 
(CVD) were at high risk according to their CRP levels although they had a low-risk 
profile according to the well-documented Framingham CVD risk score (Anderson et al. 
1991). 
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A raised CRP value is normally considered above 3mg/L, however, some studies have 
suggested that 2mg/L can lead to an increase in cardiovascular risk. The presence of 
CRP>2mg/L was found to occur in half of the adult US population (Woloshin & 
Schwartz 2005). Thus, the disease burden represented by this elevation could be highly 
relevant. The possibility exists that periodontitis could also account for some of this 
systemic inflammation (D'Aiuto et al. 2004b, Loos 2005). 
 
With the interest in CRP as a risk predictor for disease and mortality, factors 
influencing CRP are becoming increasingly investigated. Conditions not traditionally 
considered as inflammatory are being redefined, as such, because they result in an 
increase in CRP. Conversely, Kushner et al. (2006) suggested that CRP reflects cell 
injury which initiates the inflammatory response. The degree of cell injury may then 
determine the extent of CRP increase. The group also questioned whether the numerous 
diseases known to cause a minor elevation of CRP truly increase the risk for 
cardiovascular disease. This view was supported by others (Dhingra et al. 2007, 
Horowitz & Beckwith 2000) and suggested caution when inflammatory diseases, such 
as periodontitis, are believed to increase cardiovascular risk because of mild elevations 
of CRP. 
 
Dhingra et al. (2007) examined the association of inflammatory disease with CRP in 
subjects from the Framingham heart study. This study presented retrospective data from 
3,782 subjects without baseline cardiovascular events. Increasing CRP values were 
more often associated with the presence of a chronic inflammatory condition. Analysis 
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revealed that these conditions were not associated with incident cardiovascular disease. 
Therefore, the authors recommended that the predictive value of CRP for 
cardiovascular events may only be significant in those without a concomitant 
inflammatory condition. This is important because CRP is a serum marker and could 
reflect processes occurring as a result of two unrelated conditions. They recommended 
that subjects with known inflammatory diseases should not have CRP used as a 
cardiovascular risk marker. Moreover, those with an acute illness should not be tested 
until they are healthy. 
 
Of significance to the periodontal research community is whether periodontitis could be 
considered a systemic inflammatory condition. Despite periodontal treatment having a 
positive effect on circulating CRP, there may be no benefit in reducing cardiovascular 
risk. Future studies need to confirm whether periodontitis significantly increases the 
risk of cardiovascular disease in the first instance. 
 
The stimulus for hepatic CRP production is via elevated levels of pro-inflammatory 
cytokines. IL-6 is a major component released by adipose tissue and therefore, leads to 
an associated elevation in CRP. Acute illness as well as cancers and chronic 
inflammatory conditions also raise CRP levels. Of note is the finding that raised CRP is 
detected prior to the onset of clinical symptoms in inflammatory conditions such as 
rheumatoid arthritis and ankylosing spondylitis. It is unclear from these cross-sectional 
studies whether the inflammation is both contributing to the cause as well as 
representing the outcome of the disease.  
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Apart from the liver, CRP is produced by respiratory tract and renal epithelium. Animal 
studies suggested that CRP activates the classic complement pathway but may also 
contribute to host defence processes by acting as a pro-inflammatory mediator (Pepys 
& Hirschfield 2003). However, the biological significance of CRP is yet to be 
confirmed (Yeh 2005). At present, few studies have examined the collection of CRP in 
the GCF or production by gingival tissue (Fitzsimmons et al. 2010, Megson et al. 2010, 
Tüter et al. 2007). Some have suggested that the CRP levels in GCF may be utilised to 
assess a subject‟s systemic inflammatory burden. The usefulness may be limited by the 
variability in techniques to collect GCF and the relative complexity in contrast to serum 
analysis. 
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2.4. PERIODONTITIS 
2.4.1 Definition 
Periodontitis involves the destruction of the periodontal ligament, bone and the soft 
tissue which surrounds the teeth. This condition contrasts to gingivitis where 
inflammation is limited to the gingival tissue. Gingival inflammation is thought to 
precede periodontitis (Lang et al. 2009), but not all gingivitis progresses to periodontitis 
(Kinane 2001). Periodontal diseases are initiated by microorganisms in plaque. 
However, the progression from gingivitis to periodontitis is largely the result of the host 
response to the original microbial-induced tissue destruction (Kinane 2001). 
Consequently, some groups of people are at higher risk of developing periodontitis due 
to alterations in the host response to plaque. Research focussing on the destructive host 
response will help identify those at increased risk.  
 
2.4.2 Measurement of periodontitis 
The assessment of periodontal status incorporates the use of a periodontal probe. This 
periodontal probe is used to measure clinical attachment level (CAL) and probing 
pocket depth (PPD). CAL reflects past disease, whereas increased PPD in conjunction 
with bleeding on probing (BOP) represent current disease (Borrell & Papapanou 2005). 
Greater flexibility in statistical analysis is achieved when data is available for PPD and 
CAL. However, the available literature suggests that obesity is mainly associated with 
deepened PPDs (Nishida et al. 2005, Saito et al. 2005, Ylöstalo et al. 2008) but not 
CAL (Kongstad et al. 2009, Torrungruang et al. 2005). 
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2.4.3 ‘Case definition’ of periodontitis 
Tonetti and Claffey (2005) have proposed a two-tiered case definition of periodontitis. 
A low threshold case of periodontitis is characterised by proximal attachment loss of 
≥3mm in ≥2 non-adjacent teeth. The presence of proximal attachment loss of ≥5mm in 
≥30% of teeth present is defined as high-threshold periodontitis. The combined use of 
these definitions in research will allow detection of incipient periodontitis and those 
cases with substantial destruction due to severe periodontitis. Using proximal 
non-adjacent sites eliminates the inclusion of isolated attachment loss due to 
non-periodontal causes, such as toothbrush abrasion or subgingival restorative margins. 
The lack of standardised definitions for periodontitis has complicated the evaluation of 
links between periodontitis and systemic health. 
 
2.4.4 Prevalence 
The prevalence of periodontitis has generally remained stable, however, recent 
evidence suggested that the prevalence is decreasing (Hugoson & Norderyd 2008). This 
review did suggest that decreases were mainly evident in mild to moderate forms of 
periodontitis. The decrease in prevalence may reflect the influence of public awareness 
and the uptake of preventative dentistry. A key to preventing the future impact of 
advanced disease is to identify those individuals at higher risk. 
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The prevalence of periodontitis in New South Wales, Australia is 23%, which is 
comparable to the national average (Australian Institute of Health and Welfare 2008), 
see Fig. 2. This estimate is based on at least two interproximal sites having a PPD or 
CAL ≥5mm. This is similar to the recommendations made by others to detect 
low-threshold periodontitis (Tonetti & Claffey 2005). The prevalence in the same 
cohort was comparable when the number of sites with PPD≥4mm was used.  
 
 
 
 
 
 
 
Fig. 2. – Prevalence of periodontitis amongst various age groups 
(Australian Institute of Health and Welfare 2008). 
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2.4.5 Pathogenesis 
2.4.5.1 Introduction 
The pathogenesis of periodontitis involves the initiation of a destructive host response 
by microbial organisms. The ecological plaque hypothesis states that disease results 
because of a change in the local microbial environment (Marsh 1994). In periodontitis, 
the natural balance between the plaque and the host is altered. This may result in 
proliferation of organisms capable of causing tissue damage, or invoking a more 
destructive immune response. Specifically, bacterial species Porphyromonas gingivalis 
and Aggregatibacter actinomycetemcomitans have been shown to possess virulence 
factors that enable them to invade the host tissue. 
 
The gingival sulcus is shallow in health. With plaque accumulation on the tooth 
surface, the gingiva becomes inflamed (Löe et al. 1965). This is characterised by 
redness, swelling and loss of contour (Kinane 2001). BOP is able to detect histological 
signs of inflammation prior to visual changes (Greenstein et al. 1981). Gingival 
swelling causes the sulcus to become deeper where oxygen tension decreases. With 
time, a greater proportion of the bacteria involved are anaerobic and the number of 
spirochetes increases (Theilade et al. 1966). The resident neutrophils in the GCF 
attempt to control plaque accumulation through bacterial engulfment. Once the 
neutrophils are overwhelmed, they degranulate and release their contents. Tissue 
destruction will result secondary to the release of peroxidases. The damaged tissue 
releases cytokines which then promotes an inflammatory response (Kinane 2001). 
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The inflammation progresses into a chronic pattern where cytokines are continuously 
released. The cells responsible for the inflammatory process include neutrophils, 
monocytes and fibroblasts. The resultant cytokines which are released enhance the 
recruitment of leukocytes and lymphocytes into the periodontal tissues. In some 
patients, the immune response causes the degradation of the collagen fibres in the 
periodontal ligament, causing periodontitis. Histologically, an inflammatory infiltrate is 
located adjacent to the periodontal pocket with apical migration of the junctional 
epithelium (Page & Schroeder 1976). Breakdown of connective tissue and the 
periodontal ligament is evident. Furthermore, resorption of the crestal alveolar bone is 
apparent and if it continues the tooth may eventually be lost. 
 
Clinically, the presence of deepened PPD will increase the likelihood of local 
inflammation. This will further perpetuate the destructive process. Deepened PPD and 
BOP increase the risk for progression of periodontitis (Claffey & Egelberg 1995, 
Matuliene et al. 2008), however, the risk will vary between individuals. Consequently, 
the determination of these „at risk‟ groups is the focus of current literature. 
 
Risk factors for periodontitis and disease progression are classified as either modifiable 
or non-modifiable. Modifiable risk factors include diabetes mellitus, smoking and poor 
oral hygiene. In comparison, non-modifiable factors, such as genetics and gender 
cannot be altered (Page et al. 1997). Whilst genetic changes may contribute to an 
increased susceptibility there are many interdependent factors which still require 
investigation.  
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2.4.5.2 Local 
It is difficult to determine the effect of individual cytokines on the periodontium 
because of their overlapping functions and the host‟s genetic variability. Cytokines are 
released by resident cells in the periodontal tissue and include IL-1α, IL-1β, TNF-α, 
IL-6 and IL-8 (reviewed by Okada and Murakami (1998) and Graves (2008)). Cytokine 
production appears to play a role in chronic leukocyte recruitment and tissue 
destruction. A continued influx of systemic cytokines into the gingival tissue may 
enhance the local inflammatory response. However, it is unclear whether the local 
concentration of cytokines is saturated, meaning additional systemically derived 
cytokines (e.g. in obese subjects) would have no further influence on periodontal 
inflammation. 
 
The amount of cytokine collected from the gingival crevice is dependent on the pocket 
depth (Toker et al. 2008). Their study included 15 healthy controls and 15 subjects with 
aggressive periodontitis. The results indicate that the levels of IL-1β increase as pocket 
depth increases (1-3, 4-6 and >6mm). In contrast, the levels of IL-10 increased from 
shallow pockets whereas no difference was found between moderate and deep pockets. 
These results suggested that the amounts of cytokines increase with more extensive 
inflammatory lesions but findings can differ between cytokine families. 
 
The effect of periodontitis on the cytokines found in GCF has been explored in patients 
with and without chronic periodontitis. GCF samples were collected on Millipore
®
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filter paper strips (Orozco et al. 2006). Gingivitis sites were classified as having a PPD 
of ≤3mm and BOP. IL-1 and IL-18 were found to be higher from the gingivitis sites of 
periodontitis subjects compared with gingivitis sites of subjects without periodontitis. 
The periodontitis subjects showed no differences in these cytokine concentrations as the 
PPD increased (i.e. between gingivitis and periodontitis sites). This may relate to the 
sampling technique because the greater fluid volume collected in deeper sites will 
dilute the concentration of cytokines. This may otherwise have suggested that the 
presence of periodontitis has an effect equal on cytokine levels to that of increased 
PPD. 
 
A study by Fujihashi et al. (1993) confirmed that periodontitis is a local inflammatory 
condition. This group showed that gingival mononuclear cells produced IL-6, whereas 
peripheral blood mononuclear cells did not. Recently, periodontitis subjects were 
reported to have increased IL-6 in gingival tissue when compared with healthy subjects 
(Cole et al. 2008). Additionally, these results revealed that patients with diabetes and 
periodontitis had additive increases. This implied that the interaction between 
periodontitis and diabetes is partially mediated through IL-6.  
 
Serum cytokines do not accurately reflect the presence or severity of periodontitis. This 
may be due to host variability and confounding factors. Analysis of gingival tissue 
biopsies show that the levels of cytokines were higher when compared with serum. This 
confirms that these mediators are produced locally in periodontitis sites (Gorska et al. 
2003). Conversely, this was not true in subjects with low cytokine levels or in healthy 
35 
 
gingival sites. Thus, it is unclear whether raised serum levels of cytokines are reflected 
as higher GCF or gingival tissue levels. If found to be true, serum pro-inflammatory 
cytokines may potentially promote periodontal destruction with less contribution from 
the local inflammatory process. 
 
2.4.5.3 Systemic 
There is debate as to whether periodontitis is a risk factor for cardiovascular events. 
The relationship relies on the production of a systemic inflammatory response due to 
periodontitis. Gorska et al. (2003) found that the serum cytokine concentrations were 
variable and not detectable in all subjects. Furthermore, the cytokine levels did not 
correlate to clinical parameters; with other groups finding similar results (Iwamoto et 
al. 2003, Yamazaki et al. 2005). In contrast, many others have reported an association 
between periodontitis and high concentrations of systemic pro-inflammatory cytokines 
(D'Aiuto et al. 2007). Supporting a positive association; periodontal treatment (or full 
mouth extraction) resulted in reduced serum levels of inflammatory mediators (D'Aiuto 
et al. 2005, Seinost et al. 2005, Taylor et al. 2006).  
 
A prospective single-blind intervention trial was conducted to examine the effect of 
periodontal therapy on serum IL-6 and CRP (D'Aiuto et al. 2004a). The 94 subjects 
with generalised periodontitis (>30% bone loss at 50% of teeth) were followed for 6 
months. Treatment was carried out by a periodontist and consisted of non-surgical 
therapy and where necessary, tooth extraction. Active therapy was completed within 
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1-3 months and the subjects were re-examined after 2 and 6 months. The serum levels 
of IL-6 and CRP were significantly reduced between baseline and 6 months. Most 
importantly, the frequency distribution revealed that only 62% and 73% of subjects 
showed reductions in CRP and IL-6, respectively.  
 
D‟Aiuto et al. (2004a) stratified their results according to treatment response and it 
appeared that those with a better response (i.e. BOP<30%) were more likely to have 
reductions in CRP (78% vs. 62%). This supports the concept that a reduction is 
dependent on the quality of debridement. In addition, some subjects, who despite 
adequate treatment, still do not achieve improvements in systemic inflammation. This 
result was confirmed in a more recent study. Those subjects with multiple sources of 
inflammatory burden (e.g. obesity and periodontitis) were less likely to have a 
reduction in systemic inflammation following non-surgical treatment (Offenbacher et 
al. 2009). Therefore, a variety of patient groups should be studied so that subgroups that 
do not experience a reduction in systemic inflammatory markers can be identified. 
Once identified, these subjects can be excluded from studies which examine the 
beneficial systemic effect of periodontal therapy on cardiovascular health. 
 
Most studies supported the finding that individual variation is present (D'Aiuto et al. 
2004a, Iwamoto et al. 2003) which indicates that unknown variables mask the serum 
reductions. Due to the highly variable results, it cannot be assumed that periodontal 
therapy will reduce serum pro-inflammatory cytokines in all patients. Therefore, 
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research identifying confounding factors and reasons for negative outcomes need to be 
conducted.  
 
The effect of periodontitis on systemic parameters of glucose and lipid metabolism was 
evaluated in a case-control study (Lösche et al. 2000). Increased fasting glucose, total 
cholesterol, LDL and triglyceride levels were found in subjects with periodontitis 
(defined as 3 pockets of at least 4mm depth). The frequency of pathological lipid 
profiles was also greater. Due to the case definition for periodontitis and the design of 
the study, the significance of the results was unknown. It is not clear whether 
periodontitis is the result, the cause, or is confounded by these aberrations.  
 
The significance of a host trait was discussed some time ago (Ebersole et al. 1993). The 
original finding was that inflammatory mediators were elevated in clinically healthy 
sites within a subset of patients. The mediators were also elevated in samples from 
gingivitis sites. It implies that the mediators could simply reflect the developing 
inflammatory response rather that the destructive process itself and this should be born 
in mind when examining studies reporting „active breakdown‟ or progressing sites. 
 
The effect of systemic inflammation on the incidence of periodontitis is largely 
unknown. Most data relate to associations between genetic polymorphisms and 
periodontitis. More recent theories have proposed a link between a systemic 
inflammatory trait, which may originate from the metabolic syndrome or from obesity. 
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Engebretson et al. (2002) noted that IL-1β was present in shallow sites from patients 
with severe disease. This indicated that a host trait was responsible for the presence of 
this pro-inflammatory cytokine not the presence of local inflammation.  
 
A more recent study also supported the influence of a systemically derived IL-1β. 
Poorly controlled diabetics also had increased cytokines levels from clinically healthy 
sites (Engebretson et al. 2004). The GCF cytokine levels correlated well with the 
percentage of BOP sites. This suggested that the amount of cytokine at an individual 
site was correlated to the total amount of local inflammation throughout the mouth. 
This may be explained by a general systemic hyper-inflammatory state. Moreover, 
obese subjects contained higher mean full mouth IL-1β levels than controls. This may 
provide a biological reason for the increased prevalence of periodontitis in obese 
subjects (Zhong et al. 2007). 
 
The role of raised CRP was evaluated by Linden et al. (2008) who reported that the 
presence of periodontitis was associated with increased CRP over a 10 year period. At 
the same time, Fitzsimmons et al. (2010) evaluated the association between IL-1 and 
CRP with periodontal cases. This study examined the GCF and assessed the odds ratio 
for the presence of periodontitis. IL-1 and CRP appeared to be independently associated 
with periodontitis. This suggested that the inflammatory state, as assessed by IL-1 and 
CRP, are part of the cause and the consequence of periodontitis. This is assumed to be 
true because CRP is considered to be produced from the liver but appeared independent 
of the levels of IL-1. The authors, however, discussed that the study could not confirm 
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the origin of the cytokines detected in the GCF. Gingival CRP production has been 
investigated but the results are conflicting (Lu & Jin 2010, Megson et al. 2010).  
 
Fitzsimmons et al. (2010) concluded by suggesting that periodontitis could be under 
bidirectional influences. The local inflammatory response can influence distant organs 
through serum cytokines but also individuals with a hyper-inflammatory phenotype are 
predisposed to tissue destruction in response to local periodontal infection. This also 
provided a biological link that the systemic cytokines can reach the GCF.  
 
In non-diabetic individuals, the serum levels of IL-6 were similar when subjects were 
compared on the basis of gingival health (Andriankaja et al. 2009). The group 
compared healthy with „biofilm-gingival interface‟ (BGI) gingivitis subjects (i.e. ≥10% 
BOP positive sites and all PPD≥3mm). Conversely, the diabetic subjects had significant 
increases in serum IL-6 with BGI gingivitis compared with healthy controls. Due to the 
cross-sectional study design, the direction of the relationship is unclear. It was not 
apparent whether it was the diabetic state making the gingivitis more prevalent and 
thus, leading to higher serum levels of IL-6 or the that the diabetics with gingivitis were 
more sensitive to local inflammation and responded with greater production of IL-6 in 
serum and GCF. 
 
In both diabetic and non-diabetic subjects, the subject mean GCF levels of IL-1β and 
PGE2 were associated with the presence of BGI gingivitis. This supported the findings 
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of Engebretson et al. (2004) who found a correlation between IL-1α and the number of 
BOP positive sites. It suggested an interaction between local inflammation and the 
presence of diabetes but the direction was only speculative and needed confirmation in 
longitudinal studies. 
 
The biological significance of raised TNF-α was reviewed by Liu et al. (2010) and 
might relate to the increased expression and release of IL-6 from human gingival 
fibroblasts following stimulation from TNF-α (see Fig. 3). In addition, TNF-α is 
thought to modulate RANK signalling pathways, thus increasing osteoclast 
differentiation. The gingival tissue should not be considered in isolation as systemic 
cytokines may further interrupt the balance between remodelling and periodontal 
destruction. A biological connection between raised serum cytokines may result in 
greater GCF cytokines.  
 
 
Fig. 3. The role of TNF-α in bone destruction (from Liu et al. 2010). 
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Macrophages, T-cells, local fibroblasts and tissue resident macrophages secrete 
pro-inflammatory cytokines including TNF-α and IL-6 amongst others. These regulate 
osteoclastic development and activity to impact on bone remodelling processes in the 
periodontium.  
 
TNF-α participates in bone resorption by promoting differentiation of osteoclast 
progenitor cells into mature osteoclasts (Azuma et al. 2000). Similarly, Receptor 
activator of nuclear factor kappa-B ligand (RANKL) participates in osteoclast 
differentiation by facilitating cell-cell interactions. RANKL is expressed on the 
osteoblast cell membrane and binds to the RANK receptor on pre-osteoclasts (Yasuda 
et al. 1998). A monkey model was used to highlight the important role of TNF-α in 
periodontitis (Assuma et al. 1998). The authors reported reduced bone destruction when 
TNF-α or IL-1 were inhibited.  
 
A significant relationship between periodontitis and low-grade systemic inflammation 
was found in 485 subjects despite controlling for age, smoking, gender and ethnicity 
(Nibali et al. 2007). This low-grade systemic inflammation was characterised by 
increases in white cells counts, low-density lipoprotein cholesterol, non-fasting glucose 
levels and decreased high-density lipoprotein cholesterol. Unfortunately, they did not 
control for obesity and this was acknowledged as a confounder by the authors. It is 
unclear from this and other cross-sectional studies which came first; a 
pro-inflammatory state or periodontitis (Engebretson et al. 2007). Obesity may be a 
pro-inflammatory state which confounded this research. 
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Obesity has been identified as a risk indicator in recent cross-sectional studies (Al-
Zahrani et al. 2003, Saito et al. 2001, Wood et al. 2003) and was suggested to produce a 
hyper-inflammatory state due to the secretion of adipokines. This exacerbated 
inflammatory response may enhance the local periodontal tissue destruction in some 
individuals.  
 
The possibility of a true association between the presence of periodontitis and 
cardiovascular risk is complicated and requires further study. Simplistic epidemiologic 
methodology is influenced by residual confounding and spurious associations (Hujoel 
et al. 2006). Thus, more information is required to identify confounding factors and to 
understand biological mechanisms so that future studies can be designed with 
appropriate outcome variables and adequate adjustment for confounders.  
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2.5. GINGIVAL CREVICULAR FLUID 
2.5.1 Description 
GCF collection has been a popular research tool as it is less invasive than biopsy 
collection. The function of GCF is to flush debris from the gingival crevice. It 
contributes to the host defence mechanism by supplying neutrophils and 
immunoglobulin to the gingival crevice. The GCF represents a blood ultrafiltrate 
(Goodson 2003) and in the absence of inflammation is considered a transudate of 
interstitial fluid resulting from osmotic gradients (Alfano 1974). During inflammation, 
the fluid resembles a true exudate (Griffiths 2003). When this fluid passes through the 
tissues, it accumulates substances that are produced by bacteria and host cells. 
Therefore, in theory, it is an ideal diagnostic fluid. In spite of this, its collection is 
difficult, the volume is limited and the chosen technique may influence the result.  
 
It has long been established that the GCF flow rate is an indicator of local 
inflammation, with higher flow rates present in locally inflamed sites (Daneshmand & 
Wade 1976, Egelberg & Attström 1973, Lamster et al. 1986). Consequently, the 
products collected from inflamed gingival sites might have a lower protein 
concentration due to increased fluid volume. This sample dilution represents the largest 
obstacle in using GCF as diagnostic fluid.  
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2.5.2 Collection 
GCF originates from small vessels in the periodontium, collecting enzymes and 
proteins as it passes through the gingival tissue into the sulcus. When a GCF sample is 
collected the existing protein content is depleted; thus, there is a delay before protein 
levels are replenished (Lamster et al. 1989, Persson & Page 1990). Lamster et al. 
(1989) used sequential sampling to show that the highest concentration was obtained on 
the first strip and that it took up to 60 minutes for proteins to recover to baseline 
concentrations. The first GCF sample resembles extracellular tissue fluid concentration 
whereas repeated sampling may lead to protein levels similar to serum (Curtis et al. 
1988). This raised protein level could indicate trauma to the vasculature. Taken 
together, the results of these studies suggested that samples visibly contaminated with 
blood should be discarded and another site chosen for analysis to avoid repeated 
sampling. 
 
Due to the limited volume of GCF and the need for consistent samples, GCF collection 
must be carefully planned (Hatipoglu et al. 2007). GCF can be collected within the 
sulcus or at the orifice. The orifice shows greater reproducibility, whereas the 
intrasulcular location collects a greater volume (Egelberg & Attström 1973). The 
sample site location, proximal or facial, will also influence the volume (Lamster et al. 
1989). Due to the absence of clinical inflammation in healthy sites and hence, a small 
volume of GCF, collection from within the crevice would maximise the volume of fluid 
collected. 
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GCF can be collected by gingival washing, using capillary tubing or with absorbent 
filter paper strips (see Griffiths (2003) for review). The most common method utilises 
filter paper trips which are inserted at or within the gingival crevice. Gingival washing 
techniques involve irrigation with a known fluid volume and then recollection along 
with the added GCF contents. This technique is good for collecting cells but has the 
disadvantage of losing site specific data of the GCF volume and its contents. 
Alternatively, capillary tubes of a known diameter can be used. This enables accurate 
determination of volume (depending on the distance the GCF has migrated). This 
method collects GCF without dilution and has the limitation of being less useful in 
areas with minimal inflammation and hence, minimal GCF volume.  
 
An important consideration is whether the technique disturbs the crevicular 
environment or stimulates gingival fluid production. Trauma to the gingiva may cause 
haemorrhage of small vessels; and thus, contaminate the GCF sample. This is suggested 
to be of less concern with the filter paper method if used correctly (Griffiths 2003). 
Determining the ideal technique is difficult as samples cannot be directly compared. 
The initial sample will influence the crevicular environment and has the potential to 
alter GCF concentrations (Lamster et al. 1989, Persson & Page 1990) making 
comparison impossible. From the limited information above it can be seen that more 
research on the optimal method is required but it is methodologically difficult and 
expensive to conduct. 
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The volume of crevicular fluid collected at a particular site is dependent on the level of 
local inflammation (Egelberg & Attström 1973). This implies that the GCF volume is 
determined by the pressure in the crevice, which is greatest in sites with maximal 
inflammation. In one study, the GCF volume did not vary between sites within an 
individual (Lamster et al. 1989), whilst another study revealed a 50% variation (Stewart 
et al. 1993). This difference might reflect the level of plaque accumulation, with mature 
plaque being present in the later study. Therefore, it is difficult to compare GCF 
concentrations, both between and within sites. This is due to the variability in the 
volume collected which dilutes the sample, thus explaining the conflicting evidence on 
cytokine concentrations. Furthermore, it suggests why the identification of „active 
periodontitis sites‟ using cytokine concentrations is not clinically useful (Lamster & 
Ahlo 2007).  
 
Determining the amount of cytokine per standard sample time appears to give greater 
accuracy (Lamster et al. 1986). Despite Lamster‟s recommendations, many 
investigators still use the concentration of inflammatory mediators (Mantyla et al. 
2003), whilst others report both concentration and total amount of cytokines 
(Engebretson et al. 2004, Engebretson et al. 1999, Reinhardt et al. 1994, Toker et al. 
2008). Using concentration is further complicated by the fact that healthy sites often 
contain minimal GCF (Lamster et al. 1989) and evaporation of the sample fluid may 
occur (Griffiths 2003). In some studies, the volume was recorded as zero, thus making 
the concentration zero. Moreover, most of the cytokines are taken up by the strip in the 
first few seconds, after which, the concentration is diluted because additional fluid is 
47 
 
absorbed (Persson & Page 1990). Thus, the concentration will depend on the sample 
time as well as the level of inflammation. Given these limitations, the reporting of GCF 
cytokines as a concentration should be avoided.  
 
The length of time that the filter paper is in contact with the GCF will influence the 
amount of cytokines collected. Reinhardt et al. (1994) found that 30 seconds was 
insufficient to detect IL-6, whereas a previous study found that most sites contained 
IL-6 when 30 seconds was used (Reinhardt et al. 1993). Recent research has reported 
the ability to detect IL-6 within 15 second (Giannopoulou et al. 2003) or 30 second 
(Erdemir et al. 2004) samples. However, recovery of TNF-α to detectible levels may 
only reach 60% (Erdemir et al. 2004). 
 
A recent study has shown that both the concentration and total amount of IL-1β in GCF 
varies throughout the day (Bergmann & Deinzer 2008). This was the first study 
examining this effect and it suggested that clinical differences could be masked if 
samples from different time points were compared. The IL-1β in GCF is stable between 
the hours of midday to 18:00 and therefore, repeat samples should be collected between 
these times. 
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2.5.3 Storage 
Serum samples are traditionally stored in freezers with temperatures below -70
o
C. 
Liquid nitrogen freezers appear to be most appropriate for long-term storage and 
provide a consistent storage temperature (Tworoger & Hankinson 2006). In 
comparison, mechanical freezers show variable temperature recordings in different 
parts of the freezer. Few studies have examined the effect of storage temperature on 
inflammatory markers in serum (Exley & Cohen 1990), and limited data exists for GCF 
(Herrmann et al. 2001). It is difficult to assess the impact of storage temperature in 
long-term studies where differences could be attributed to either sample degradation or 
a change in the laboratory assay. Therefore, empirical suggestions of -70
o
C have been 
made (Kenis et al. 2002, Tworoger & Hankinson 2006).  
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There is limited information surrounding the effect of GCF sample storage on the 
recovery rates of IL-6 and TNF-α. Whilst investigating GCF elastase activity, 
Herrmann et al. (2001) conducted a pilot study on various storage methods. The group 
published their results and showed that 100% of the elastase activity was maintained 
after 72 hours. This was found for storage at -22
o
C and -80
o
C, see Fig. 4. No published 
data exist for storage beyond 72 hours, nor for any other cytokines.  
 
 
Fig. 4. The effect of storage temperature on the degradation of GCF elastase activity 
(from Herrmann et al. 2000). 
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The levels of cytokines found in biological samples are influenced by many other 
factors apart from temperature. Flower et al. (2000) determined that the levels of IL-6 
and leptin were not affected by freeze thaw cycles, whereas TNF-α displayed 
alterations after a third cycle. In a second study, it was shown that refrigeration of 
samples 8 hours prior to freezing was better in preserving TNF-α and IL-1β in cervical 
mucous when compared with snap freezing (Panicker et al. 2007). Considering the 
paucity of evidence, a priori techniques for storage may be followed (Toker et al. 2008, 
Tüter et al. 2007).  
 
2.5.4 Analysis 
Cytokines have been analysed within medical and dental research using the enzyme 
linked immunosorbent assay (ELISA). ELISA was originally developed from the 
radio-immunosorbent techniques of Wide and Porath (1966). These procedures have 
been modified by others to avoid the use of a radioisotope (Engvall & Perlmann 1971, 
Van Weemen & Schuurs 1971). In brief, antibodies are conjugated with enzymes. The 
fluid containing the molecule of interest is fixed to a surface. The enzyme linked 
antibodies are washed over the surface and the bound samples release a coloured signal. 
This signal is read using absorbance at 450nm (Van Weemen & Schuurs 1971). ELISA 
is the most common method used to detect cytokines in GCF (Engebretson et al. 2002, 
Fitzsimmons et al. 2010, Gamonal et al. 2000, Kurtis et al. 1999, Reinhardt et al. 1994). 
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2.6. OBESITY, INFLAMMATION AND PERIODONTITIS 
2.6.1 Biologic mechanism 
The mechanism connecting periodontitis to obesity involves either a 
hyper-inflammatory state, an aberrant lipid metabolism, or insulin resistance 
(Nishimura & Murayama 2001, Pischon et al. 2007, Saito & Shimazaki 2007). Fig. 5 
illustrates how pro-inflammatory cytokines may be involved. Investigating the 
biological relationship between obesity and periodontitis will aid the interpretation of 
evidence supporting a link between cardiovascular disease and periodontitis. 
 
Fig. 5. Inflammatory cytokine interactions (Adapted from Pischon et al. 2007) 
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The connection between obesity and the periodontium was first described by Perlstein 
and co-workers (1977). Obese rats displayed histological changes in the blood vessels 
supplying the periodontium. The observed hyperplasia and hypertrophy led to intimal 
thickening and diminished blood flow. Many years later researchers continue to gather 
information and explain these observations on a molecular level (Singhal 2005).  
 
In addition to these histological changes, obesity results in an impaired lymphocyte 
responsiveness, which increases the risk of infection. Tanaka et al. (1993) investigated 
the T and B cell responses of obese and non-obese subjects. They found that the obese 
subjects had depressed blastogenesis of B-cells and impaired stimulation of 
T-lymphocytes. Furthermore, the immune response recovered when the subjects lost 
weight. This showed that obese people have impaired immunity which recovers 
following weight loss (and a reduction in the pro-inflammatory state).  
 
Mice with diet-induced obesity were investigated in a ligature-induced periodontitis 
model (Amar et al. 2007). A silk ligature was soaked in broth containing P. gingivalis 
and placed into the gingival sulcus. The obese mice displayed greater alveolar bone loss 
with both ligature-induced periodontitis and intravenous injection of P. gingivalis when 
compared with controls. Serum analysis revealed that production of systemic IL-6 and 
TNF-α was initially impaired. However, when measured two hours after the challenge, 
the levels were higher in these obese mice compared with the lean mice. This suggested 
that the immune response is blunted, with lower cytokines levels initially, followed by 
insufficient deactivation.  
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The above animal findings suggested that periodontal damage is greater in obese mice 
compared to lean mice and that this may be due to impaired IL-6 and TNF-α production 
or their prolonged activation. Whilst impaired cytokine production is contradictory to 
the results of others, the prolonged activation further supports obesity as a chronic 
pro-inflammatory state. The initial decrease may relate to the experimental nature of an 
acute rather than a chronic infection. This model supports the existence of a cytokine 
interaction between obesity and periodontal infection. 
 
Studies examining risk-factors for periodontitis have recognised that the host response 
is central to the aetiology of periodontitis (reviewed by Salvi et al. 1997). Patients with 
Type 1 diabetes mellitus have increased levels of inflammatory mediators; PGE2 and 
IL-1 in their GCF (Salvi et al. 1997b). The authors suggested that this finding may 
represent a systemic inflammatory response trait and that the high local levels of these 
mediators may lead to a greater severity of periodontitis. This has not yet been 
investigated in subjects with type 2 diabetic or obesity. 
 
An inflammatory model linking obesity, diabetes and periodontitis was proposed and 
investigated (Genco et al. 2005). The NHANES III data were utilised to examine the 
relationship between obesity, periodontal disease and diabetes. Periodontitis was 
defined as having a mean loss of attachment of 1.5mm. Fasting blood glucose 
>126mg/dl was used to define a subject as diabetic. Subjects were stratified according 
to BMI with those ≥27 being classified as overweight. The multivariate regression 
model also considered other factors known to impact on the periodontal condition. This 
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data revealed that an increased BMI was positively and significantly associated with the 
severity of attachment loss. The results were modified by insulin resistance. The 
subjects with the highest quartile of insulin resistance had increased odds for severe 
attachment loss (OR=1.48). In contrast, overweight individuals in the lowest quartile 
showed no association.  
 
The second part of the Genco et al. (2005) study involved analysis of serum TNF-α and 
its soluble receptor (sTNF-α) from a subset of 1221 adults from the control group of a 
myocardial infarction and periodontitis study. The highest and lowest quartile BMI 
groups in this study were compared. The highest levels of serum TNF-α and sTNF-α 
were present in those with a higher BMI, however, a positive correlation with 
periodontal disease was found only in those with a low BMI. This was postulated to 
occur because obesity is likely to result in greater TNF-α production compared with 
periodontitis thus, overpowering its effect. More recently, Saxlin et al. (2009b) have 
shown that periodontitis was associated with serum IL-6 but not TNF-α and might also 
explain the non-significant finding in the study. 
 
Currently, the presence of IL-6 in the GCF of obese subjects has not been directly 
investigated. Despite this, it is known that GCF levels of TNF-α are increased in obese 
children (Khosravi et al. 2009) and adolescents without periodontitis (Lundin et al. 
2004). Thus, the relationship between systemic cytokines (released from adipose tissue) 
to the cytokines present in the GCF is unclear. Investigations are required to determine 
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whether the increased adipokine levels in serum and GCF translate into a heightened 
inflammatory response in the gingiva.  
 
IL-6 and TNF-α, among others, are thought to be secreted by monocytes and 
lymphocytes following a lipopolysacharide challenge at the gingival interface. These 
inflammatory mediators elicit clinical signs of inflammation, as well as bone and 
connective tissue destruction (Hughes & Howells 1993, Liu et al. 2010, Salvi et al. 
1997a). Furthermore, the secretion of matrix metalloproteinases and the differentiation 
of monocytes into multinucleated osteoclasts is mediated by IL-6 (Salvi et al. 1997a).  
 
Babel et al. (2006) reported that subjects with gene polymorphisms of inflammatory 
mediators were associated with periodontitis. In this cross-sectional study, subjects 
were divided according to the presence of periodontitis and gene polymorphisms. Of 
most interest was the finding that high phenotypic IL-6 production was significantly 
associated with periodontitis in this predominantly Caucasian population (Babel et al. 
2006). Thus, it may be plausible that higher serum IL-6 as a result of obesity may 
influence the periodontal condition because it results in the same inflammatory 
outcome.  
 
These gene polymorphisms have the potential to increase the local concentrations of 
inflammatory mediators. Similarly, it is also plausible that inflammatory mediators 
secreted by adipose tissue can increase the local concentration of IL-6 in the gingiva. 
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This could potentially promote tissue destruction and therefore, account for the 
increased prevalence of periodontitis in this population. 
 
Lundin et al. (2004) investigated the presence of TNF-α in the serum of obese 
adolescents. The study design involved GCF collection using standardised filter paper 
which was inserted into 4 pre-determined sites. The adolescent subjects have a mean 
BMI 38.6±7.7kg/m
2
 and were grouped according to the presence of a pathological 
pocket (4mm or greater). They found that BMI was correlated to the levels of TNF-α 
found in GCF and that the presence of a pathological pocket did not influence the 
results. They concluded that the TNF-α released from adipose tissue was found in the 
GCF at levels in proportion to the level of obesity. Unfortunately, serum was not 
collected and it is unclear whether the serum and GCF cytokine levels would be related. 
It might be possible that the cytokines in the gingival tissue were produced locally 
rather than arising from the adipose tissue. In addition, their definition of a pathological 
pocket might be insufficient to detect a difference. The mean PPD of the pathologic 
pockets was not presented and therefore, the severity of „periodontal destruction‟ was 
unknown. 
 
Recently, the results of Lundin et al. (2004) were further explored in a larger study 
(Khosravi et al. 2009). One hundred and seventy eight children aged 8-10 years were 
dentally examined and their BMI measured. Plasma was analysed for insulin resistance 
and GCF for the presence of TNF-α. The correlation between age-specific BMI, levels 
of TNF-α and plasma fasting insulin was calculated. The results showed a positive 
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correlation between adiposity (BMI) and the GCF levels of TNF-α which appears to be 
mediated through insulin resistance. The mechanism may involve the over-expression 
of adipokines in obesity (particularly TNF-α) thus, influencing the metabolism of 
insulin. Genco et al. (2005) suggested that this, in turn, augments the systemic hyper-
inflammatory response. 
 
Genco et al. (2005) proposed that obesity leads to insulin resistance as a result of 
altered insulin signalling due to TNF-α. This insulin resistance can develop into 
diabetes mellitus and therefore, increase the risk of periodontal infection. Their model 
suggests that the periodontal tissues are primed by a hyper-inflammatory state which 
results in an exaggerated response to infecting organisms. Irrespective of the presence 
of diabetes, this hyper-inflammatory response has been suggested to occur because of 
the systemic inflammation caused by excess adipose tissue and adipokine secretions. 
Diabetes might further enhance this inflammatory state or contribute via alternative 
mechanisms, e.g. impaired immune response or wound healing (King 2008). 
 
Recent data from non-obese subjects has suggested that serum lipid levels are 
associated with periodontitis (Saxlin et al. 2008). In contrast, Genco and co-workers 
(2005) reported that the relationship between BMI and periodontitis was not influenced 
by cholesterol, triglycerides and CRP. Therefore, there appears no need to exclude 
subjects with dyslipidaemia and hypercholesterolemia in periodontitis studies.  
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Simvastatin, a medication used to lower serum lipids, was reported to have an 
anti-inflammatory effect. A human study showed that the expression of the cytokines 
IL-6, IL-8 and the chemokine MCP following administration of simvastatin (Rezaie-
Majd et al. 2002). The impact of statin use on tooth loss in periodontitis patients was 
investigated in a retrospective cohort study (Cunha-Cruz et al. 2006). The variable 
effect on tooth loss was attributed to a lack of control for confounding factors.  
 
The effect of statin medications on the periodontium was investigated by Saxlin et al. 
(2009a). A cross-sectional study involving 2,032 subjects was used to assess the 
association between satin use and periodontal infection (defined by the number of 
periodontal pockets ≥4mm or ≥6mm). A weak negative relationship was found when 
the analysis was restricted to those subjects with plaque present (adjusted OR=0.7). A 
similarly weak association was found when only BOP in one or more sextants were 
analysed. In contrast, subjects without BOP were more likely to have a greater number 
of teeth with increased with statin use (RR=1.7-3.1). Collectively, the data revealed that 
the possibility of protective effect of statin medication was only seen in those with 
dental plaque and gingival bleeding. 
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The systemic inflammatory response of obese subjects may be altered by the 
administration of corticosteroid medications. Intra-articular corticosteroid injection 
provides symptomatic relief in obesity related knee osteoarthritis (Jordan et al. 2003). 
This local injection was shown to result in serum changes lasting about 1 week 
(Armstrong et al. 1981). Renvert and co-workers (2009) examined the anti-
inflammatory effect of systemic prednisone administration on periodontal parameters 
and serum cytokine levels. Although the serum levels of CRP, IL-6 and IFN-γ 
decreased, they returned to 90% of pre-treatment levels within 1 month. In contrast, 
PPD and BOP were not altered. Fig. 6 shows the kinetics of serum CRP alteration. 
Therefore, corticosteroid medications have limited affect on the periodontium at four 
weeks. This implies that subjects should be excluded if these medications have been 
taken in the preceding four weeks. 
 
Fig. 6. The effect of oral prednisone (CRx-102) administration on the levels of CRP in 
serum (from Renvert et al. 2009). 
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2.6.2 Association studies 
Awareness of a connection between obesity and periodontitis was re-established 
through a letter published in the New England Journal of Medicine (Saito et al. 1998). 
The authors reported that obesity led to a higher odds ratio of having periodontitis. The 
subject group was included in a latter report where an additional 402 patients were 
examined (Saito et al. 2001). In this sample of 643 dentate adults, most of whom were 
female, the odds ratio of suffering from periodontitis increased along with BMI. The 
quality of this data was limited by its cross-sectional nature and its crude measurement 
of periodontal status. Calculation of oral hygiene was based on time spent brushing, 
whilst disease severity was scored according to the worst PPD in a quadrant. Despite 
these limitations, the results of this study suggested that the link between periodontitis 
and cardiovascular disease should be reconsidered. Obesity appears to be a common 
factor to both diseases and may therefore, act as a confounding factor. 
 
A dose-response relationship was observed between BMI and the prevalence of 
deepened PPD >3.5mm (Nishida et al. 2005) in a group of Japanese subjects. The effect 
of obesity was second only to smoking, although confounding by diabetes was not 
controlled. The effect of obesity was most significant when the BMI was ≥26, which is 
the threshold for obesity within an Asian population (Gallagher 2004, Kim et al. 2004). 
In Japanese women, Saito and co-workers (2005) found that periodontitis (determined 
by the mean pocket depth) was associated with the highest quartile of BMI, WHR and 
body fat. However, no statistically significant relationship was found between CAL and 
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the various measures of adiposity and independent of diabetic status. This suggested 
that obesity was related to current rather than a past history of periodontitis.  
 
Wood et al. (2003) using the NHANES III data found significant correlations between 
CAL, PPD and obesity. Whilst the authors noted that the WHR was the most significant 
variable for attachment loss, there were only minor differences in the level of 
significance when pocket depth and BMI were compared with WHR. Subcutaneous fat 
was not significant and thus, highlights the impact of fat distribution on the results. The 
major limitations of this study include the crude data collection method on smoking and 
diabetic history. Smoking was analysed as current or non-current, whilst diabetes was 
self-reported. In addition, the use of a Caucasian population limits the generalisation of 
the results. Nevertheless, the study population was large and provided further stimulus 
for research into periodontitis and obesity. 
 
The NHANES III data has also been utilised by Al-Zahrani and co-workers (2003). The 
authors identified young adults to have an increased odds ratio for the presence of 
periodontitis and obesity using both BMI and WHR. Above the age of 35, obesity was 
not significantly associated with periodontitis. This result might be explained by the 
presence of unknown confounders or by the masking effect of stronger risk factors 
present in older subjects. The presence of periodontitis was defined by a minimum of 
one site with ≥3mm CAL and a PPD of ≥4mm. This might be considered a low-
threshold to detect a „periodontitis case‟. Using this threshold might be too sensitive 
and therefore, would be indiscriminate in detecting patients with periodontitis. It was 
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also possible older subjects would have experienced isolated attachment loss due to 
non-periodontal causes. 
 
Al-Zahrani‟s group (2005) also investigated the relationship between bone loss 
(measured by full mouth radiographs) and BMI. In this case-control study, obese 
subjects under 40 years of age have an odds ratio of 2.67 for alveolar bone loss. In 
contrast, subjects over the age of 40 displayed no significant association. Females were 
also observed to have a stronger relationship between obesity and periodontitis. A 
similar effect was seen when smoking history was evaluated; with non-smokers having 
a significant association. The results of this study confirm previous studies showing that 
smoking masks the effect of obesity (Dalla Vecchia et al. 2005, Ylöstalo et al. 2008). 
Similarly, traditional periodontitis risk factors increase with age, explaining why the 
association is strongest in younger populations.  
 
Higher thresholds to detect periodontitis were utilised by Bühlin et al. (2003). It was 
observed that subjects with a BMI >26 (for men) or >25 (for women) had an odds ratio 
of 4.5 for the presence of periodontitis. The strength of this Swedish case-control study 
is limited by the health related behaviours of obese patients. In this study, it was 
reported that obese patients also performed poorly in exercise tests. This may reflect 
different attitudes to overall health. This influence has been investigated in 
cross-sectional studies (Al-Zahrani et al. 2005a, 2005b, 2006, Sanders et al. 2009). 
Merchant et al. (2003) found that physical exercise was associated with a lower risk for 
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periodontitis in the physicians study. These factors should be considered when 
designing case-control studies that involve obese subjects and non-obese controls. 
 
Dalla Vecchia et al. (2005) explored the relationship between obesity and periodontal 
health in a Brazilian population. A sample of 706 subjects (aged 30 to 65) were 
examined clinically. High threshold periodontitis was defined as ≥30% of teeth with at 
least 5mm of attachment loss. Males, females and non-smokers were analysed 
separately. This study revealed that obese non-smoking females were 3.4 times more 
likely to have periodontitis than healthy weight individuals. In comparison, smokers 
and males have no significant relationship. It was likely that stronger risk factors (i.e. 
gender and smoking) overpowered the effect of obesity in this population of obese 
non-smoking males.  
 
The link between obesity and periodontitis was examined in Western European males 
aged 60-70 years. In this study, low-threshold periodontitis was identified by the 
presence of at least two teeth with non-contiguous inter-proximal sites with ≥6mm loss 
of attachment and at least one pocket of ≥5 mm. High-threshold periodontitis was 
identified when ≥15% of sites had CAL ≥6mm combined with one site having a deep 
pocket (≥6 mm). A positive association was found for low-threshold periodontitis 
(Linden et al. 2007). In contrast, an association with high-threshold periodontitis and 
obesity was not found. This difference was thought to occur because of the adjustment 
for smoking habits, which were more likely to be associated with advanced disease. 
Consideration should also be given to the smaller sample size in the high-threshold 
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group. This was one of the few studies finding an association in older male subjects, 
Moreover, obesity remained significant even after adjusting for smoking habits and 
diabetes.  
 
The results of Linden et al. (2007) were in accordance with the existing periodontal 
literature (Borrell & Papapanou 2005). The prevalence of periodontitis in obese 
subjects was higher in those who smoke, belong to a lower SES, attended the dentist 
less frequently and did not brush as often. In their multivariate analysis, smoking was 
the strongest factor associated with periodontitis, furthermore, increasing cigarette 
consumption potentiated the effect of obesity on periodontitis. No association was 
found in overweight subjects when compared with obese subjects. 
 
The relationship between periodontitis and obesity was assessed by Torrungruang et al. 
(2005) in a cross-sectional study involving Thai adults. No association was found when 
BMI or WC was used to measure obesity. Major differences in the study design and 
subject demographics may account for this finding when compared with previous 
studies. Of particular note, was the grading of periodontitis. This is the only study that 
attempted to correlate the severity of periodontitis with obesity. No other studies have 
examined whether obesity led to more severe periodontitis, rather they examined only 
the presence of periodontitis. Nonetheless, this study showed that obesity alone is 
unlikely to account for periodontal disease severity. It is likely that traditional risk 
factors would overpower the influence of obesity as a contributing factor. 
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Compared with other studies the Torrungruang et al. (2005) group also examined Thai 
adults over the age of 50. Most other cross-sectional surveys on obesity and 
periodontitis have shown minimal association with older patients (Al-Zahrani et al. 
2003, Linden et al. 2007). Additionally, this study relied solely on CAL to measure 
disease severity and a periodontal heath group was not included. The use of both CAL 
and a threshold PPD may be more valid in detecting current periodontitis rather than a 
focussing on a history of periodontal destruction. Consequently, the exact relationship 
between obesity and periodontitis is unclear, especially in older individuals. This study 
suggests a weak or non-existent association in subjects over the age of 50 years due to 
the increased exposure of confounding factors with age. 
 
The relationship between obesity and periodontal variables was further explored in the 
Copenhagen city heart study (Kongstad et al. 2009). Similar to other studies, full mouth 
CAL was not associated with increased odds for periodontitis, in fact, it was inversely 
related. On the other hand, BOP was significantly associated with obesity. This study 
did not evaluate PPD in the multivariate analysis, which would have been interesting. 
 
Contrary to the many studies reporting an increase in periodontitis with obesity, the 
opposite has also been reported. A cohort study found that the extent of periodontitis 
was associated with a 5% decrease in weight over 2 years (Weyant et al. 2004). This 
was considered to be the result of a higher systemic inflammatory burden. This may 
occur due to the presence of periodontitis or changes in nutrient intake. The authors 
controlled for the number of teeth in the final analysis, which suggested that 
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masticatory efficiency plays a minor role in their findings. This was in contrast to other 
groups who found the number of masticatory units to be a modifying factor (Ritchie 
2007). Therefore, the Weyent et al. group (2004) introduced a separate mechanism 
which can account for inconsistent associations between obesity and periodontitis. 
Older individuals with fewer, mobile and painful teeth had lower nutrient intake and are 
therefore, less likely to be obese. 
 
A positive relationship between BMI and periodontitis was noted in Japanese university 
students aged 18-24 years old using the community periodontal index (CPI) as a 
measure of periodontitis (Ekuni et al. 2008). They found that the prevalence of 
periodontitis was correlated with BMI, meaning that even in non-obese subjects the 
periodontitis was more prevalent as BMI values increased. Apart from the crude 
periodontal classification (based on the CPI), they did not assess smoking history nor 
the presence of diabetes. Moreover, the prevalence of periodontitis and obesity in this 
group was small. The authors report that smoking rates were low and suggest that the 
short exposure time in young subjects is less likely to result in periodontal destruction. 
These factors may confound the positive correlation found in this study. The authors 
could have considered excluding smokers to strengthen their results in a manner similar 
to Reeves et al. (2006). 
 
A large scale cross-sectional study was carried out in Finland (Ylöstalo et al. 2008). 
The authors examined 2,841 non-diabetic subjects aged 30-49. Periodontitis was 
defined by the number of teeth with pockets ≥4mm or ≥6mm. An association was found 
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between BMI and the presence of pockets ≥4mm after controlling for smoking habits. 
The presence of diabetes was determined by a questionnaire. The study suggested that a 
weak exposure-response with obesity was evident in subjects who have never smoked. 
The results of this study confirm the findings of others (Al-Zahrani et al. 2003, Saito et 
al. 2001, Wood et al. 2003). Furthermore, it was acknowledged that additional research 
is needed to determine the nature of this association. 
 
Support for an association was found in a cross-sectional study from Jordan. Three 
hundred and forty subjects were recruited from accompanying persons attending 
medical outpatient clinics (Khader et al. 2009). A periodontitis case was defined as 
having PPD≥4mm and CAL≥3mm at a minimum of 4 teeth. BMI, high WC and high 
fat percent were found to be significantly associated with the presence of periodontitis. 
The authors adjusted for age, plaque index and number of missing teeth which were 
found to be significant in their regression model. Smoking was not significant and they 
discussed that the low plaque scores may have influenced this finding. Diabetes was 
found to be significant in the univariate analysis but was not controlled for in the 
multivariate analysis. This was the major limitation of this study. 
  
The influence of behavioural aspects of obesity was highlighted by Reeves et al. 
(2006). Their study examined the association between body weight and WC with 
periodontitis in adolescents. The NHANES III data revealed that in 17-21 year olds a 
1cm increase in WC was associated with a 5% increased risk for periodontitis (adjusted 
OR, 1.05 (Reeves et al. 2006)). In contrast, 13-16 year olds showed no association. 
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Obese subjects with periodontitis were more likely to be male, African-American or 
„other‟ race, in the lowest socioeconomic group, without a dental visit for 3 years or 
more and had lower calcium intake. Smokers were excluded from this study. 
  
Reeves and co-workers (2006) discussed their results in relation to health risk 
behaviours and the presence of unhealthy dietary patterns. This includes insufficient 
micronutrient intake and excess sugar and fat content. They discuss that the risk for 
periodontal disease may also result from changes in host immunity and/or increased 
stress levels. Reeves and co-workers (2006) conclude that the association may relate to 
health awareness rather than biological mechanisms. This view is supported by Linden 
et al. (2007) who showed that periodontitis was present in those who gained 30% more 
weight from young adulthood. However, this relationship was attenuated when 
controlling for poor health related behaviour. 
 
Sanders (2009) evaluated the effect of physical activity on the relationship between 
CRP and periodontitis. The cross-sectional study from Australia involved 751 subjects 
(359 periodontal cases and 392 controls). Periodontal data and GCF were collected. 
Generally, the levels of CRP and IL-1β in GCF were lower in those undertaking regular 
exercise. Further to this, their results suggested that subjects with periodontitis had a 
dose-response reduction in CRP with increasing exercise. The authors conclude that 
physical activity can influence the level of systemic inflammation and that this may 
result in protection from periodontitis, however, longitudinal studies are required. 
Interestingly, the study also confirmed that overweight subjects (BMI >25) have higher 
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levels of CRP and IL-1β in the GCF. It would be interesting to confirm the relationship 
between the serum and GCF in this subgroup. In addition, the study found that the 
diabetic and overweight status appeared not to influence the odds of lowered CRP with 
increasing exercise. 
 
Complementing the results of the Sanders et al. (2009) study, Al-Zahrani and 
co-workers (2005b) reported that individuals with a higher quality diet were 40% less 
likely to have periodontitis. They also confirmed the positive influence of exercise and 
maintaining a healthy weight on periodontal status. 
 
Gursoy et al. (2006) evaluated periodontitis patients with or without diabetics and 
obesity. Diabetes mellitus clearly influenced the mean PPD, however, the addition of 
obesity did not strengthen this difference. The obese group showed marginally greater 
PPD than healthy controls but the difference was not significant. This study is limited 
by the potential risk of probing error which is more significant because of the low 
statistical power. 
 
More recent evidence has focused on health behaviour and obesity as part of the 
metabolic syndrome. Han et al. (2010) evaluated the association between metabolic 
syndrome and periodontitis. The highest CPI score was used to classify an individual. 
The presence of low threshold periodontitis was greater among Korean subjects with 
metabolic syndrome. The presence of additional illnesses contributing to the metabolic 
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syndrome increased the odds ratio for periodontitis. This might reflect a lower health 
attitude rather than a biological connection. Males, older subject age, smoking and 
infrequent tooth brushing were also associated with periodontitis. The authors admit 
that the positive association is probably due to residual confounding. 
 
Benguigui et al. (2010) recently evaluated the relationship between metabolic 
syndrome, insulin resistance and periodontitis. After complete adjustment for 
confounders, the metabolic syndrome was not associated with periodontitis. In contrast, 
insulin resistance (using the HOMA index) was associated with severe periodontitis. 
This relationship was minimally affected when diabetic subjects were excluded. 
Interestingly, the association between insulin resistance on periodontitis was not 
significant in non-smokers. Obesity and periodontitis were not associated following 
adjustment. The authors supported an earlier hypothesis that insulin resistance mediates 
the relationship between obesity and periodontitis (Genco et al. 2005, Khosravi et al. 
2009). 
 
Insulin resistance (or impaired glucose tolerance) occurs when the pancreas either does 
not release enough insulin or the cells become resistant to the insulin. This state can 
lead to increased glucose levels and therefore, has been researched in the context of 
periodontitis and diabetes. Saito et al. (2006) examined radiographs of older men who 
had attended a medical evaluation upon retirement. This study revealed that impaired 
glucose tolerance was associated with alveolar bone loss (OR=4.27). This result was 
independent of obesity and most likely due to the older age of these subjects. 
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Amongst the recent articles reporting on association between periodontitis and 
metabolic syndrome, an interesting study reports that periodontitis was associated with 
the development of metabolic syndrome (Morita et al. 2010). Further studies are 
required to clarify this new finding. 
 
Taken together, the above studies confirm that a cross-sectional relationship exists 
between obesity and the presence of periodontitis. It should be remembered that these 
association studies were mostly limited to populations in Brazil, Japan, Scandinavia and 
the USA. Furthermore, inconsistent definitions for a „periodontitis case‟ were used. 
Consensus group definitions (Page & Eke 2007, Tonetti & Claffey 2005) were not used 
in any study, hence, comparison between studies is difficult. It should also be noted that 
a cross-sectional examination does not have the capability to establish temporal 
relationships or biological plausibility. Therefore, further investigations focusing on the 
biological mechanisms are needed to clarify a connection between obesity and 
periodontitis. 
 
2.6.3 Directions for future research 
Obesity is considered an inflammatory condition which results in increased levels of 
serum pro-inflammatory cytokines (Bastard et al. 2000, Yudkin et al. 1999). The pro-
inflammatory state may be one mechanism which explains the association between 
periodontitis and obesity. High levels of pro-inflammatory cytokines released into the 
serum by adipose cells may modulate the destructive immune response to plaque 
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bacteria (Pischon et al. 2007). This may explain the biological connection between 
periodontitis and systemic conditions (Zhong et al. 2007). 
 
At present, no study has examined the relationship between serum and GCF cytokines 
in an obese patient group. Non-obese subjects have lower levels of serum cytokines and 
therefore, these cytokines may be less frequently detected from the GCF of healthy 
gingival sites. In periodontitis subjects the IL-6 cytokine may be undetectable in up to 
50% of GCF (Gorska et al. 2003) and serum samples (Loos et al. 2000). TNF-α was 
also found to be undetectable. Smokers, with elevated serum IL-6 and TNF-α, had 10% 
and 40% of sites which were undetectable, respectively (Erdemir et al. 2004). This will 
obviously influence the mean amount of IL-6 and TNF-α collected in the GCF of these 
subjects.  
 
It is unclear whether subjects with elevated serum cytokines, e.g. in obese subjects, also 
have higher levels detected in the GCF of healthy sites. Further to this, it cannot be 
assumed that the cytokines found in serum remain active when they are transported to 
the gingival crevice via the gingiva. Studies on other serum proteins have suggested 
variable correlations between serum and GCF samples (Smith et al. 1985, Tew et al. 
1985, Tsalikis et al. 2004). The most relevant cytokines linking obesity and 
periodontitis are IL-6 and TNF-α. Therefore, obese subjects with abundant serum levels 
of IL-6 and TNF-α, are ideal subjects to detect a correlation between serum and GCF.  
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PART B: CLINICAL STUDY 
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3. AIM 
The aim of this pilot study was to investigate the correlation between GCF and serum 
levels of IL-6 and TNF-α in obese subjects. 
 
3.1 Objectives 
The main objective was to elaborate on the cytokine relationship between the serum 
and GCF. It is important to determine whether the serum cytokine levels are accurately 
reflected in GCF. A positive correlation would help support a biological connection 
between obesity and periodontitis. This would confirm whether the cytokines released 
into the serum from adipose tissue are transported to the gingival tissue and hence, the 
GCF.  
 
3.2 Null Hypothesis 
“That the levels of IL-6 and TNF-α in the serum of obese subjects are not correlated to 
the amounts found in the GCF” 
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4. MATERIAL AND METHODS 
4.1 Experimental design 
A descriptive cross-sectional examination was used to analyse the levels of IL-6 and 
TNF-α present in serum and the GCF. The cytokine level was compared within each 
subject to determine the presence of a correlation between GCF and serum. Ethical 
approval was obtained from the Sydney West Area Health Service Human Research 
Ethics Committee. 
 
4.2 Subject recruitment 
Subjects were recruited from an obesity clinic at Westmead Hospital which aims to 
provide a multi-disciplinary approach to the treatment of obesity. In addition to 
monitoring the weight of obese patients, the clinicians diagnose and manage obesity 
related conditions, such as diabetes and cardiovascular disease. Additional subjects 
were recruited from patients attending the dental clinics of Westmead Hospital. Invited 
subjects gave informed consent and were classified as obese (BMI≥30). Detailed 
inclusion and exclusion criteria are presented in Table 1. 
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Table 1. Inclusion and exclusion criteria 
Inclusion criteria 
 ≥18years of age and the ability to give informed consent 
 BMI≥30kg/m2 
 Minimum of two healthy gingival sites for GCF sampling 
 Diagnosed with periodontitis, gingivitis, or periodontal health 
Exclusion criteria 
 Current smokers (≥1 cigarette/day) 
 Poorly controlled diabetes (HbA1c ≥8%) 
 Patients requiring antibiotic prophylaxis prior to dental treatment 
 Antibiotics or systemic corticosteroids within the last month 
 Periodontal therapy within the last six months 
 General scaling in the last month 
 Current inflammatory or infectious disease 
 Current medications influencing the periodontal tissues 
 Current pregnancy or breast feeding 
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4.3 Clinical measures 
Recruited patients from the Westmead Hospital obesity clinic attended the Periodontics 
department at Westmead Centre of Oral Health. Following consent procedures, the 
periodontal status was visually examined to assess possible GCF collection sites. GCF 
sample collection was followed by a comprehensive periodontal examination including 
recording of clinical attachment level (CAL), probing pocket depth (PPD) and bleeding 
on probing (BOP). Third molars were not included. GCF samples were collected prior 
to periodontal charting to avoid stimulation of the gingival tissues and blood 
contamination. Immediately following the successful collection of GCF and periodontal 
charting, the subjects were sent for venous blood sample collection within 60 minutes. 
See Fig. 1 for a flow chart illustrating the data collection protocol. 
Fig. 1. Flow diagram illustrating data collection protocol 
Patients identified and contacted from the obesity clinic database 
Consent obtained and Medical/Dental history recorded 
GCF collection prior to periodontal examination 
Blood collection and serum processing 
GCF and serum storage at -70
o
C 
Elution of GCF cytokines and ELISA processing 
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4.4 GCF sample collection 
GCF samples were required from two healthy (non-bleeding) sites for each subject. 
Their mean was used for analysis. Additional samples were taken to allow for sites 
which were later excluded due to BOP. Another two samples were taken from sites 
showing clinical signs of gingival inflammation (subsequently assessed by BOP and 
PPD≤4mm). Suitable sampling sites were selected and isolated with cotton rolls. 
Supragingival plaque was removed with a probe and cotton pledgets. The area was 
gently air-dried and filter paper strips were placed in approximal locations for 30s. A 
single standardised periopaper strip (Proflow, Oraflow Inc. Plainview, NY, USA) was 
inserted into the gingival crevice until resistance was felt without exceeding a depth of 
1mm (see Fig. 2). If the strip was contaminated with blood it was discarded and a new 
sample site was selected. Each sample was placed into separate microcentrifuge tubes 
for storage at -20
o
C. The samples were transferred to -80
o
C within four hours where 
they were stored until further analysis (Khosravi et al. 2009, Tüter et al. 2007). 
 
 
 
 
 
Fig. 2. GCF collection technique 
Adapted from 
Griffiths (2003) 
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4.5 Serum Sample collection 
Immediately following the collection of GCF and assessment of periodontal clinical 
measures (CAL, PPD, BOP), the subjects attended the Institute of Clinical Pathology 
and Medical Research (ICPMR) blood collection service. Here, 10ml of venous blood 
was obtained within 60 minutes from the antecubital fossa using serum tubes (BD 
Vacutainer® Serum Tubes, North Ryde, NSW, Australia). These tubes were transferred 
to the Institute for Dental Research where they were left at room temperature for 30 
minutes to maximise clot contraction. In the case of incomplete clot contraction; the 
clot was separated from the glass tube using a sterile cotton swap and incubated for a 
further 30 minutes at 37
o
C (Sanyo CO2 incubator, Sanyo, North Ryde, NSW, 
Australia). The samples were subsequently chilled on ice for 90 minutes prior to 
centrifuging at 1400rpm (Eppendorf 5810R, Eppendorf South Pacific, North Ryde, 
NSW, Australia) for 5 minutes at 4
o
C. The superficial supernatant was removed using a 
1ml micropipette and stored in microcentrifuge tubes at -80
o
C (Thermo Ultra-low 
temperature freezers, ThermoScientific, K.I. Scientific, Lane Cove, NSW, Australia) 
until the day of ELISA analysis. Separate serum tubes were sent to the ICPMR for 
analysis of HbA1c (in diabetics) and fasting blood glucose (in non-diabetics). 
C-reactive protein (CRP) was measured using a sandwich immunoassay (VITROS, 
Ortho Clinical Diagnostics, Mulgrave, VIC, Australia).  
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4.6 ELISA analysis 
GCF 
Cytokines were eluted from thawed filter paper with 100µl of 1x phosphate buffered 
saline (PBS). A vortex mixer (SVM1, Selby Biolab, Clayton, Victoria, Australia) was 
used to assist elution of cytokines from each filter paper. Two 10 second intervals were 
used. A micro-centrifuge (Heraeus Biofuge 15, K.I. Scientific, Lane Cove, NSW, 
Australia) was used for 5 minutes at 2000 rpm to further enhance mixing. Each GCF 
sample was subsequently analysed for IL-6 and TNF-α, in duplicate, using 
commercially available ELISA Kits (Quantikine, R&D Systems, Minneapolis, MN, 
USA).  
 
Briefly, 20µl of each sample (or standard) was added to microplate wells. PBS was 
added to make up a volume of 100µl for IL-6 and 200µl for TNF-α. Reagents were 
added sequentially according to the manufacturer‟s instructions. Due to frothing of 
reagents and loss of volume, 80% of each reagent was added to the ELISA plates. This 
was consistent in all sample processing. An orbital shaker (Bioline Shaker, Adelab, 
Thebarton, SA, Australia) was used during incubation in accordance with the ELISA 
kit instructions, however, the speed was reduced to 120 rpm.  
 
After the recommended incubation times, the absorbance was measured using a 
microplate reader at 490nm (Bio-Rad Benchmark Microplate reader, Bio-Rad 
laboratories, Regents Park, NSW, Australia). Absorbance correction was made at a 
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wavelength of 655nm. The minimum detectable dose according to the manufacturer is 
0.039 pg/mL for IL-6 and 0.106 pg/mL for TNF-α. Results were recorded as a total 
amount of cytokines (in pg) per 30s sample for each subject. 
 
Serum 
Serum samples were thawed and centrifuged at 2000 rpm for 5 minutes along with the 
GCF samples. Thereafter, 20µl of standard or serum were added to microplate wells 
coated with a monoclonal antibody specific for TNF-α or IL-6 (Quantikine. R&D 
Systems, Minneapolis, MN, USA). PBS and the ELISA reagents were added exactly as 
described above.  
 
Following appropriate incubation times, the absorbance was measured at 490nm with a 
microplate reader and corrected at 655nm. The serum TNF-α and IL-6 levels were 
extrapolated from a curve constructed from TNF-α and IL-6 standards. Results were 
recorded as serum concentrations of cytokines (in pg/ml) for each subject. Serum 
samples for each subject were included in the same ELISA kit as the corresponding 
GCF samples to avoid variation between assays. 
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4.7 Statistical Analysis  
The distribution of cytokine levels in serum and GCF were examined to identify 
potential outliers. The relationship between cytokines (IL-6, TNF-α) in serum and GCF 
were correlated using Spearman‟s correlation analysis and statistical significance of this 
coefficient was determined using two-sided p values (p<0.05). Furthermore, agreement 
of the cytokine values between GCF and serum were evaluated using a Bland-Altman 
analysis. This test quantifies inter-method agreement for individual patients over the 
entire range of clinical values of a given parameter (Bland & Altman 1999). In the 
present study, this method was used to measure agreement between serum and GCF 
cytokine levels within each subject. 
 
To the best of our knowledge no previous studies have evaluated the levels of IL-6 and 
TNF-α in the GCF and serum of obese subjects. Given the absence of prior data that 
were directly relevant to the present study, a formal power calculation was not possible 
and therefore, the study was conducted as a pilot study.  
 
Initially ten samples were used to confirm laboratory procedures. At this stage, it was 
noted that there were a high number of GCF samples below detection threshold. The 
inability to detect a cytokine at a gingival site despite its presence in serum supports a 
low correlation. Therefore, samples below the detection threshold were given arbitrary 
values of (detection limit/√2). 
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5. RESULTS 
5.1 Subject Recruitment 
A total of 46 subjects agreed to attend for a dental examination and from this 39 
participants initially met the inclusion criteria. Of these, one subject was considered a 
poorly controlled diabetic (HbA1c >8%) and their data were excluded. Another subject 
could not wait for serum collection and therefore, the GCF data were excluded. One 
serum sample had incomplete data on diabetic status and the subject was excluded. No 
adverse events were recorded for GCF or serum sample collection. The samples from 
the remaining 36 subjects were processed using the ELISA technique. 10 samples had 
to be excluded due to laboratory error. Therefore, the data from 26 subjects were 
included in the final analysis (shown in Fig. 3).  
Subjects attending for examination 
 (n=46) 
Subjects meeting inclusion criteria and 
providing GCF and serum samples  
(n=39) 
Subjects included in final analysis 
(n=26) 
Subjects excluded due to abnormal 
serum results or laboratory error  
(n=13) 
Fig. 3. Flow diagram outlining subject recruitment  
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5.2 Subject Demographics 
Subject variables are summarised in Table 2. The mean age was 53.92 ± 11.13 (33-74) 
and 17/26 (65.4%) subjects were female. Of the recruited subjects 10/26 (38.5%) had 
Type 2 diabetes mellitus, with glycaemic control (HbA1c) ranging from 5.5 to 7.9%. 
Fasting blood glucose ranged from 4.1-7.0mmol. Non-diabetic subjects had a fasting 
BSL≤6mmol. Subject 7 had a mildly elevated BSL (7mmol) which is an indication of 
insulin resistance and is the cut-off value for a diagnosis of Type 2 diabetes (American 
Diabetes Association. 2010). This subject, however, had an HbA1c level of 6.7% which 
lies within the inclusion criteria of the current study. Individual data is presented in 
Table 3. 
 
 
Table 2. Summary of subject variables 
SUBJECT VARIABLES Mean ± SD (Range) 
Mean age ± SD (Range) 53 ± 11.13 (33-74) 
Sex (Females) 17/26 
Diabetes (Type 2) 10/26 
Mean fasting BSL ± SD (mmol/L) 4.98 ± 0.70 (4.1-7.0) 
Mean HbA1c ± SD (%) 6.42 ± 0.80 (5.5-7.9) 
Mean serum CRP ± SD (mg/L) 9.62 ± 7.14 (<3-26)* 
Median serum IL-6 ± IQR (pg/mL) 157.593 ± 300.06 (4.40-1081.89) 
Median serum TNF-α ± IQR (pg/mL) 18.983 ± 62.56 (0.08-1560.02) 
* CRP reported as ≤3mg/L by the ICPMR laboratory were recorded as 3mg/L 
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Table 3. Periodontal variables and relevant medical conditions and medications of each 
subject  
Subject Sex 
Medical Conditions/Medication 
Smoking 
Percentage of PPD  
OA COX OSA AB OTHER BOP 
PPD 
1-3mm 
PPD 
4-6mm 
7 M      Never 17% 97% 3% 
12 F      Never 26% 97% 3% 
13 F Y     Never 52% 73% 26% 
14 F Y     Never 63% 90% 10% 
15 F Y    Actonel Never 58% 52% 47% 
16 F      Never 39% 100% 0% 
17 F Y Y Y   Never 44% 100% 0% 
18 M  Y Y Y  Former 9% 100% 0% 
19 M Y     Never 74% 63% 35% 
20 F Y Y   Fosamax Former 32% 91% 8% 
21 F Y  Y   Former 22% 87% 13% 
22 F      Never 7% 100% 0% 
23 F Y     Former 17% 100% 0% 
24 M      Never 39% 96% 4% 
25 F Y   Y 
Prednisone 
6weeks prior 
Never 23% 100% 0% 
26 M   Y   Former 11% 100% 0% 
27 M      Never 35% 95% 5% 
28 F Y    Plavix Never 29% 100% 0% 
29 M   Y   Never 41% 75% 25% 
30 F Y  Y   Former 48% 91% 9% 
31 F    Y  Former 14% 99% 1% 
32 M   Y   Former 17% 100% 0% 
33 F   Y  Methotrexate Never 38% 98% 2% 
34 F Y  Y   Never 32% 99% 1% 
35 M Y  Y   Never 22% 98% 2% 
36 F      Former 44% 97% 3% 
OA: osteoarthritis, COX: cyclooxygenase inhibitors (e.g. aspirin, NSAIDs)  
OSA: Obstructive sleep apnoea, AB: antibiotics within 3 months 
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The inflammatory status of each subject was quantified using serum CRP values 
determined by the ICPMR laboratory. As shown in Fig. 4, the serum CRP levels were 
highly variable and seven samples were below the detection threshold of 3mg/L. The 
median (±IQR) serum concentration of pro-inflammatory cytokines were 157.593 ± 
300.06 mg/mL and 18.983 ± 62.56 mg/mL for IL-6 and TNF-α, respectively. 
 
 
Fig. 4. Scatter plot showing serum samples levels for individual subjects. IL-6 and 
TNF-α (pg/mL) are presented on the left axis while CRP (mg/L) values are on the right.  
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5.3 Clinical findings 
Periodontal characteristics are shown in Table 3. Twenty one of the 26 subjects had 
>90% of sites with shallow probing depth (PPD ≤3mm). This reflects the low level 
periodontitis in the study subjects. The mean BOP value was 33% (7-74).  
 
5.4 Cytokine detection 
The proportion of samples above the ELISA detection limit was greater in serum when 
compared with GCF samples. Table 4 summarises the detection frequency of cytokines 
in serum and the GCF from healthy and gingivitis sites. Serum CRP, IL-6 and TNF-α 
levels for each subject are presented in Table 5. 
 
Table 4. Percentage of serum and GCF samples above detection 
threshold for IL-6 and TNF-α 
 IL-6 TNF-α 
Serum 100% 64% 
Healthy GCF 73% 52% 
Gingivitis GCF 95% 36% 
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Table 5. Subject data for levels of CRP, TNF-α and IL-6 in serum samples 
Subject 
Serum 
CRP (mg/L) IL-6 (pg/mL) TNF-α (pg/mL) 
7 6.00 49.997 62.635 
12 14.00 657.047 52.924 
13 3.00* 373.572 0.075* 
14 6.00 320.832 0.075* 
15   3.00* 349.400 56.308 
16 19.00 78.105 6.510 
17 22.00 730.296 45.479 
18 5.00 817.463 91.500 
19 19.00 1469.410 3751.099 
20 10.00 339.877 164.591 
21 6.00 27.648 18.983 
22 5.00 32.025 18.983 
23 3.00* 52.992 179.872 
24 3.00* 14.285 12.746 
25 24.00 157.593 40.185 
26 6.00 1081.893 NR 
27 3.00* 282.239 9.512 
28 3.00* 34.271 0.075* 
29 11.00 4.403 0.075* 
30 3.00* 5.635 0.075* 
31 26.00 43.201 0.075* 
32 14.00 39.814 0.075* 
33 12.00 80.152 0.075* 
34 11.00 239.962 0.075* 
35 6.00 265.827 775.520 
36 7.00 168.217 449.206 
MEAN 
(S.D) 
9.62--   
(7.14)-- 
249.870-  
(289.290)- 
138.202 
(327.064) 
NR: Not recorded 
* Below detection limit 
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The median GCF cytokine levels are presented in Table 6. No significant difference 
was found between the median amounts of IL-6 collected from healthy or gingivitis 
GCF samples (p=0.1498). Similarly, the median amount of TNF-α in GCF samples did 
not differ between sites (p=0.2246). The scatter plots in Fig. 5 highlights the inter-
individual variability in the GCF samples. Subject level data is presented in Tables 7 
and 8. The level of TNF-α in subject 19 was not consistent with the other samples and 
was considered an outlier in subsequent analyses. 
 
Table 6. Summary of GCF cytokine amounts (pg/30 second sample)  
GCF CYTOKINES Healthy Gingivitis   
GCF IL-6 (Median ± IQR) 3.084±6.691 
(n=26) 
5.818±14.925  
(n=22) 
p=0.1498*  
GCF TNF-α  (Median ± IQR) 0.319±1.366 
(n=25) 
0.075±0.514    
(n=22) 
p=0.2246*  
* Mann-Whitney U test 
 
 
 
 
 
 
 
Fig. 5. Scatter plots highlighting the inter-individual variability in the amounts of IL-6 
and TNF-α found in GCF samples (units in pg/30s). 
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Table 7. Subject data for IL-6 detection in serum and GCF samples 
Subject 
Serum  
(pg/ml) 
GCF  
(pg/30 second sample) 
Healthy Gingivitis 
7 49.997  0.657 NR 
12 657.047  0.027* NR 
13 373.572  12.123 NR 
14 320.832  4.908 9.693 
15 349.400  0.027* 41.496 
16 78.105  0.027* 1.635 
17 730.296  69.440 77.571 
18 817.463  4.102 34.793 
19 1469.410  55.377 46.953 
20 339.877  0.027* 17.409 
21 27.648  0.027* 2.440 
22 32.025  3.172 0.027* 
23 52.992  0.027* 1.071 
24 14.285  0.887 2.903 
25 157.593  7.211 5.138 
26 1081.893  57.867 NR 
27 282.239  5.852 6.497 
28 34.271  2.996 6.676 
29 4.403  0.640 2.996 
30 5.635  0.025 0.610 
31 43.201  1.872 0.302 
32 39.814  1.379 0.702 
33 80.152  4.259 2.965 
34 239.962  8.662 7.892 
35 265.827  21.872 35.497 
36 168.217  4.628 14.820 
MEAN  
(S.D) 
249.870  
(289.290)` 
10.311 
(19.356)` 
14.549  
(20.221)` 
MEDIAN  
(IQR) 
       157.593 
       (300.06)` 
              3.084 
(6.691)‟ 
              5.818 
(14.925)` 
NR: Not recorded 
* Below detection limit 
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Table 8. Subject data for TNF-α detection in serum and GCF samples 
Subject 
Serum  
(pg/ml) 
GCF  
(pg/30 second sample) 
Healthy Gingivitis 
7 62.635 0.464 NR 
12 52.924 12.195 NR 
13 0.075* 0.075* NR 
14 0.075* 0.075* 0.690 
15 56.308 4.852 0.075* 
16 6.510 0.339 0.075* 
17 45.479 0.318 0.075* 
18 91.500 4.949 0.075* 
19 3751.099# 1.164 0.075* 
20 164.591 0.075* 0.149 
21 18.983 0.075* 0.042 
22 18.983 1.441 0.075* 
23 179.872 0.339 0.075* 
24 12.746 1.711 0.075* 
25 40.185 4.019 1.524 
26 NR NR 1.025 
27 9.512 1.025 21.371 
28 0.075* 6.440 11.058 
29 0.075* 0.075* 0.283 
30 0.075* 0.075* 0.075* 
31 0.075* 0.075* 0.075* 
32 0.075* 0.075* 0.075* 
33 0.075* 0.075* 0.075* 
34 0.075* 0.075* 3.208 
35 775.520 0.075* 0.075* 
36 449.206 0.075* 0.690 
MEAN  
(S.D) 
138.202---  
(327.064)--- 
1.606- 
(2.872) 
1.833`  
(4.973)- 
MEDIAN  
(IQR) 
18.983O   
(62.56)O0 
  0.319- 
(1.366) 
0.075`  
(0.514)- 
NR: Not recorded 
* Below detection limit 
# Possible outlier 
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5.5 Correlation analysis 
The serum concentration of IL-6 was significantly correlated to the amounts found in 
the GCF samples. The correlation was highest for gingivitis samples (r= 0.79, p=.0001) 
compared with the GCF from healthy sites (r=0.48, p=0.03). There was no correlation 
for TNF-α (r=-0.19, p=0.40) and (r=0.27, p=0.22), respectively (Table 9). Correlation 
graphs are shown in Fig. 6 and 7. The relationship between serum and GCF samples 
varied between subjects and therefore, subject level data is presented in Table 10 and 
11. An arbitrary value (detection limit/√2) was given for samples below the ELISA 
detection threshold rather than recording as zero to enable statistical comparison.  
 
Table 9. Correlation coefficients for serum and GCF cytokines 
 IL-6 TNF-α 
Serum vs GCF 
(Healthy) 
r=0.48, p=0.03 r=0.27, p=0.22 
Serum vs GCF 
(Gingivitis) 
r=0.79, p=0.0001 r=-0.19, p=0.40 
Spearman‟s correlation, significance p<0.05 
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 Fig. 6. Correlation graphs for IL-6 (Spearman‟s coefficient shown on graph) 
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TNF-A Correlation
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Fig. 7. Correlation graphs for TNF-α (Spearman‟s coefficient shown on graph)
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Table 10. Subject level data showing the relationship between detection of IL-6 in 
serum and GCF samples from healthy and gingivitis sites 
Relative IL-6 in Serum and GCF 
Subject 
Serum vs GCF 
(Healthy) 
Serum vs GCF 
(Gingivitis) 
Percentage of sites 
BOP 
PPD 
1-3mm 
PPD 
4-6mm 
7 76.14 NR 17% 97% 3% 
12 24335.06 NR 26% 97% 3% 
13 30.82 NR 52% 73% 26% 
14 65.37 33.10 63% 90% 10% 
15 12940.72 8.42 58% 52% 47% 
16 2892.79 47.76 39% 100% 0% 
17 10.52 9.41 44% 100% 0% 
18 199.29 23.49 9% 100% 0% 
19 67.74 79.89 74% 63% 35% 
20 12588.03 19.52 32% 91% 8% 
21 1024.00 11.33 22% 87% 13% 
22 10.10 1186.13 7% 100% 0% 
23 1962.66 49.46 17% 100% 0% 
24 16.10 4.92 39% 96% 4% 
25 21.85 30.67 23% 100% 0% 
26 18.70 NR 11% 100% 0% 
27 48.23 43.44 35% 95% 5% 
28 11.44 5.13 29% 100% 0% 
29 6.88 1.47 41% 75% 25% 
30 228.75 9.24 48% 91% 9% 
31 23.08 143.16 14% 99% 1% 
32 28.86 56.71 17% 100% 0% 
33 18.82 27.03 38% 98% 2% 
34 27.70 30.41 32% 99% 1% 
35 12.15 7.489 22% 98% 2% 
36 36.35 11.35 44% 97% 3% 
MEDIAN 
(Range) 
2265.38` 
(6.88-24335.06) 
83.79 
(1.47-1186.13) 
33% 92% 8% 
NR: Not recorded 
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Table 11. Subject level data showing the relationship between detection of TNF-α in 
serum and GCF samples from healthy and gingivitis sites 
Relative TNF-α in Serum and GCF 
Subject 
Serum vs GCF 
(Healthy) 
Serum vs GCF 
(Gingivitis) 
Percentage of sites 
BOP 
PPD 
1-3mm 
PPD 
4-6mm 
7 135.00 NR 17% 97% 3% 
12 4.34 NR 26% 97% 3% 
13 1.00 NR 52% 73% 26% 
14 1.00 0.11 63% 90% 10% 
15 11.60 750.77 58% 52% 47% 
16 19.19 86.81 39% 100% 0% 
17 142.98 606.39 44% 100% 0% 
18 18.49 1220.00 9% 100% 0% 
19 1262.33 19592.13 74% 63% 35% 
20 2194.55 1105.45 32% 91% 8% 
21 253.10 453.98 22% 87% 13% 
22 13.1737 253.10 7% 100% 0% 
23 530.22 2398.30 17% 100% 0% 
24 7.45 169.95 39% 96% 4% 
25 10.00 26.37 23% 100% 0% 
26 NR NR 11% 100% 0% 
27 9.28 9.28 35% 95% 5% 
28 0.01 0.00 29% 100% 0% 
29 1.00 0.01 41% 75% 25% 
30 1.00 0.26 48% 91% 9% 
31 1.00 1.00 14% 99% 1% 
32 1.00 1.00 17% 100% 0% 
33 1.00 1.00 38% 98% 2% 
34 1.00 1.00 32% 99% 1% 
35 10340.27 241.77 22% 98% 2% 
36 5989.41 5989.41 44% 97% 3% 
MEDIAN 
(Range) 
``837.98 
(0.01-10340.27) 
`1495.82 
(0.00-19592.13) 
33% 92% 8% 
NR: Not recorded 
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5.6 Bland-Altman analysis 
The Bland-Altman analysis is presented in Table 12 and Fig. 8 for IL-6. The results for 
TNF-α are shown in Table 13 and Fig. 9. The 95% limits of agreement are represented 
by the horizontal red lines. The graphs illustrate, on a log scale, that there was generally 
poor agreement and high variability between cytokine levels in serum and GCF 
samples. The IL-6 levels in serum and gingivitis samples showed a more consistent 
distribution around the mean on the log scale, however, the wide limits of agreement 
indicated weak agreement between the two parameters.  
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Fig. 8. Bland-Altman analysis for IL-6 
Table 12. Bland-Altman analysis for IL-6 
 
Serum vs GCF 
(Healthy) 
Serum vs GCF 
(Gingivitis) 
Mean (Log) 0.995 3.070 
Upper limit of 
agreement (Log) 
14.474 5.792 
Lower limit of 
agreement (Log) 
-12.484 0.348 
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Table 13. Bland-Altman analysis for TNF-α 
 
Serum vs GCF 
(Healthy) 
Serum vs GCF 
(Gingivitis) 
Mean (Log) 5.652 2.937 
Upper limit of 
agreement (Log) 
47.578 11.291 
Lower limit of 
agreement (Log) 
-36.274 -5.418 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Bland-Altman analysis for TNF-α 
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6. DISCUSSION 
The aim of this study was to investigate the correlation between serum and GCF levels 
of IL-6 and TNF-α in obese subjects. The results demonstrated a significant correlation 
between the serum concentration of IL-6 and the amount collected from the GCF. No 
significant correlation was seen for TNF-α. Generally, the correlation coefficients were 
low and agreement between the two values was poor. It is likely that unknown factors 
influence these correlations owing to the highly variable serum and GCF relationship 
between subjects. The exception to this was the correlation between the IL-6 in serum 
and gingivitis GCF samples which was high and showed a greater level of agreement. 
The general lack of correlation might have implications for future research which aim 
to investigate the distant impact of systemic inflammation, especially when GCF and 
serum cytokines are evaluated independently. 
 
This is the first study to report on the serum and GCF correlations for TNF-α and IL-6 
in an obese population. Previous reports investigating these cytokines in non-obese 
subjects are limited by the number of samples below detection threshold (Boström et al. 
1999, Gorska et al. 2003). Therefore, little is known about the relationship between the 
serum and GCF levels of IL-6 and TNF-α. Studies have shown that obese subjects have 
abundant cytokines in the serum due to cytokine release from adipose tissue (Khaodhiar 
et al. 2004, Park et al. 2005). It may be speculated that the raised serum cytokines are 
transported at higher levels into the gingival tissue and GCF. This has been assumed in 
the two major studies investigating the relationship between BMI and the levels of 
TNF-α in the GCF of obese subjects (Khosravi et al. 2009, Lundin et al. 2004).  
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The lack of serum data is a limitation of the previous studies (Khosravi et al. 2009, 
Lundin et al. 2004) and was discussed by both groups. Khosravi et al. (2009) indicated 
that they would process their stored serum samples to determine if a correlation exists 
with the levels of TNF-α found in their GCF samples. Although their data are yet to be 
published, it would be interesting to compare their results with the current study. They 
examined children whereas the current study involved adult subjects. The current study 
questioned the assumption that a higher serum inflammatory response results in 
increased cytokine levels in the gingival tissue (measured from GCF samples). Whilst 
previous reviews have assumed that cytokines in GCF samples were raised in 
proportion with that in the serum sample, this was not found in our results.  
 
The present study showed that the presence of IL-6 in serum was not well correlated 
with the GCF samples from healthy sites (r=0.48) and agreement was poor. In contrast, 
the IL-6 in serum and gingivitis GCF samples was highly correlated (r=0.79) and 
showed good agreement. This suggested a low level of variability between the 
correlation of serum and gingivitis GCF samples. With regards to TNF-α, there was no 
significant correlation between serum and GCF samples. Strengthening the 
non-significant correlation, the level of agreement according to the Bland-Altman 
analysis was very poor. The interval between upper and lower limits was wide which 
confirmed the highly variable relationship between serum and GCF samples for TNF-α.  
 
The presence of soluble TNF-α receptors has been reported in the obesity literature and 
was thought to explain the lack of correlation between BMI and serum levels of TNF-α 
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(Mohamed-Ali et al. 1999). Soluble TNF-α receptors released by adipose tissue bind 
TNF-α and reduce its detection in serum. Similarly, the presence of soluble receptors 
might explain why TNF-α was not consistently detected in the serum or GCF samples 
in the current study. The reduced detection of TNF-α possibly accounts, to some extent, 
for the lack of correlation. Alternatively, the soluble TNF-α receptor may bind the 
circulating TNF-α and this might differ between subjects. In addition, the influence of 
this receptor might vary between the serum and gingival tissue. This is an area which 
may require further investigation as other cytokine receptor-substrate families may 
behave in a similar manner.  
 
The weak correlation between serum and healthy samples suggested that the presence 
of IL-6 in serum was not found in similar proportions in the GCF samples from healthy 
sites. In contrast, the positive correlation and high level of agreement between serum 
and gingivitis GCF samples might infer that a higher level of systemic inflammation 
influences the inflammatory reaction in the gingiva. This might be in proportion to the 
levels of IL-6 found in serum. Alternatively, it could also be argued that local 
inflammation in the gingival tissue could have a systemic effect as described previously 
(Andriankaja et al. 2009). The local IL-6 produced by the inflamed gingival tissue 
could be transported into the serum. The current study is unable to establish the 
direction of this relationship. Perhaps future studies in this area could collect biopsy 
material and determine the amount of IL-6 and IL-6 mRNA in the gingival tissue using 
similar methodology to that of Megson et al. (2010) who recently evaluated gingival 
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CRP production. The benefit of this type of investigation would be to determine the 
amount of local IL-6 production versus that arising from the serum. 
  
Current opinion suggest that a hyper-inflammatory response is one of the mechanisms 
explaining the link between obesity and periodontitis (Pischon et al. 2007). The 
cytokines released by adipose tissue may up-regulate the immune response to plaque 
bacteria. However, based on the present investigation, it cannot be assumed that serum 
cytokines influence the gingival tissue as these mediators were not consistently detected 
in all subjects. This means that the increased odds of having periodontitis in the 
presence of systemic inflammation (Fitzsimmons et al. 2010, Linden et al. 2008) may 
be due to different pathways which act independently or in conjunction with systemic 
inflammation. Recent data suggested that insulin resistance might play a role (Genco et 
al. 2005, Khosravi et al. 2009) although many other factors are yet to be evaluated. 
 
Due to the difficulty in finding suitable control subjects it was not possible to evaluate 
differences in the prevalence of periodontitis or to compare the cytokine levels between 
obese and non-obese subjects. Obese adults are a difficult population to study due to the 
presence of multiple co-morbidities as a consequence of excess body weight. 
Furthermore, the influence of various psychological traits on obesity and periodontitis 
should be considered. In a univariate analysis obese individuals were shown to have 
higher levels of smoking exposure, anxiety and depression and lower levels of 
optimism and satisfaction with life (Dumitrescu & Kawamura 2010). When a 
multilevel regression analysis was applied these factors were no longer significant. This 
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probably reflects a significant overlap in the health behaviour, attitude and 
psychological factors of the obese. Dumitrescu and Kawamura (2010) further 
highlighted the features of obese subjects which complicate the selection of a control 
group in clinical trials involving obese populations. 
 
To reduce the effect of confounding factors, large patient databases are required to 
essentially find „healthy obese‟ subjects with few co-morbidities. This will enable 
comparison of obese and non-obese subjects with less variation in medical illnesses, 
lifestyle and socioeconomic factors. The current patient group was chosen to 
investigate a principle, that is, the correlation of certain cytokines between GCF and 
serum. This population was the ideal group to study as the abundant cytokines in serum 
would reduce the chance of having levels below detection threshold. The patient served 
as their own control (i.e. comparing serum with GCF) which also limited some sources 
of the variability between subjects. 
 
The cytokines investigated in this study have been previously evaluated in the serum of 
obese and non-obese subjects. Numerous reports within the medical literature confirm 
that IL-6, TNF-α and CRP are raised in obese subjects. However, the raised TNF-α did 
not correlate with BMI values (Khaodhiar et al. 2004). A recent review suggested that 
periodontitis is associated with a serum inflammatory response (Loos 2005).  
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Both obesity and periodontitis have been linked to cardiovascular disease and this 
cytokine relationship may be one of the mechanisms explaining the link. Confusing the 
issue is the finding that periodontitis is associated with obesity. It is not yet clear 
whether the connection is due to shared risk factors (e.g. smoking, diabetes, 
socioeconomic status, poor health behaviour) or whether a pro-inflammatory cytokine 
profile connects obesity, periodontitis and cardiovascular disease. The result of the 
current study suggested that both serum and GCF need to be analysed when cytokine 
profiles are examined. 
 
Previous studies have shown that systemic inflammation may be reduced with 
periodontal treatment (Offenbacher et al. 2009) or full mouth extraction (Taylor et al. 
2006). Periodontal therapy was shown to reduce the serum levels of IL-6, TNF-α and 
CRP (D'Aiuto et al. 2004a, Iwamoto et al. 2001). The magnitude of change was 
variable and partially relates to the pre-treatment cytokine levels (Paraskevas et al. 
2008). A recent multicentre investigation evaluating the systemic response to 
periodontal therapy revealed that the levels of serum cytokines did not change in obese 
subjects (Offenbacher et al. 2009). This implies that studies attempting to reduce 
cardiovascular risk with periodontal therapy need to exclude obese subjects. Obviously, 
this patient group have such a large inflammatory burden that periodontal therapy alone 
will not reduce the risk of cardiovascular disease. Similarly, a previous study found that 
the serum CRP levels were not reduced in smokers following full mouth extraction 
(Taylor et al. 2006). 
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Study Design 
The results of this study are limited by the type of patients examined. The study was not 
designed to compare the present results with studies involving non-obese patients. 
Instead, the design of this study allowed testing of a biological connection between 
serum and GCF. The investigated cytokines are common to obesity and periodontitis 
and may explain the interaction between these conditions. However, many other factors 
may influence the interaction. The impact of periodontal disease status (periodontitis 
versus gingivitis) on the current results remains untested. The enrolled patients in this 
study were generally from a lower socioeconomic background with poor dental 
awareness and health behaviour. Despite this, the presence of periodontitis according to 
the criteria recommended by Tonetti and Claffey (2005) was very low. Therefore, to 
describe the periodontal status of the subject group, frequency of BOP, shallow (1-
3mm) and deepened (≥4mm) probing depths were presented without assigning a 
periodontal diagnosis.  
 
In the current study, a visual measure of inflammation was not used, instead bleeding 
on probing was used to classify a site as healthy or inflamed (gingivitis). Correlating 
cytokine levels with an increasing Gingival Index (Löe & Silness 1963) was not an aim 
of the current study. Recently, this relationship was evaluated in subjects with 
experimental gingivitis (Trombelli et al. 2010) and diabetes (Salvi et al. 2010). These 
studies differ from the current study in that analysis of GCF and the gingival index 
were recorded longitudinally from the same site in each patient, thus limiting error. A 
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concern with the gingival index is that it has low reproducibility with an intraclasss 
correlation of 0.25 (Marks et al. 1993).  
 
The variable systemic characteristics of obese subjects mean that it may be inaccurate 
to compare gingival indices between subjects. Ideally, this would be investigated by 
comparing sites with different degrees of gingival inflammation within the same 
subject, which is impractical. Therefore, the current study used bleeding on probing to 
determine the presence of inflammation as it is considered an objective method and 
forms part of the normal periodontal charting routine. 
 
The relationship between impaired glucose tolerance, obesity and periodontitis should 
also be considered (Dandona et al. 2004). The relationship between these diseases is 
very complex and involve the interactions between common cytokines (Nishimura & 
Murayama 2001). This study was not designed to exclude or segregate subjects based 
on their diabetic status or their level of impaired glucose tolerance. Diabetic patients 
were excluded if they had poor glycaemic control. The decision to exclude subjects 
with an HbA1c >8% was based on previous studies which have shown that the amounts 
of IL-1β in GCF were higher in poorly controlled diabetics compared with those having 
a HbA1c ≤8% (Engebretson et al. 2004). Poorly controlled diabetes has been associated 
with increased BOP (Seppala et al. 1993) and therefore, would have influenced the 
sampling of healthy and gingivitis (BOP positive) sites in this study. 
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The current protocol excluded subjects who had consumed systemic antibiotics or 
corticosteroids within the last month. The choice to use this timeframe was influenced 
by the difficulty in recruiting subjects. Obese patients are more likely to develop 
infections (Tanaka et al. 1993, Ueta et al. 1993) and therefore, it was common for 
potential subjects to be prescribed antibiotics by their general medical practitioner. The 
frequency of antibiotic intake in obese subjects would have also made it difficult to 
enrol a comparable control group.  
 
The effect of corticosteroid medication on serum CRP is short-term as the level 
rebounds to near baseline 4 weeks after the administration of the corticosteroid 
(Renvert et al. 2009). Furthermore, Renvert et al. (2009) showed that the effect of 
corticosteroids on clinical periodontal variables was not significant. The effect of other 
classes of medication on the periodontium might not be relevant in the current study 
because the samples were compared within each subject. The exception would be 
medications which alter the gingival appearance or BOP which would make sampling 
difficult (e.g. gingival overgrowth secondary to calcium channel blockers).  
 
It was not the intention of the study to correlate the BMI with the level of periodontitis 
or to the levels of serum or GCF cytokines as they have been reported previously 
(Khaodhiar et al. 2004, Khosravi et al. 2009, Lundin et al. 2004, Park et al. 2005, Wood 
et al. 2003). Therefore, patients were not stratified according to their BMI. The 
correlation between BMI, periodontitis and serum cytokines is best achieved with large 
population studies. All subjects were confirmed to have a BMI ≥30kg/m2 and were 
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considered obese according to the WHO criteria (2004). Although statistical correction 
was not required to satisfy the aim of the present study, accounting for these variables 
would require much large sample sizes and adequate distribution of subjects. This 
would have severely complicated patient recruitment.  
 
Large scale cross-sectional studies have investigated the presence of cytokines in 
relation to systemic and local periodontal variables. Unfortunately, the limited volume 
of GCF creates problems when assessing multiple cytokines. In comparison, the 
relative ease and increased volume of serum make it an easy target for cytokine 
analysis. This was clearly evidenced in the studies by the Offenbacher group 
(Andriankaja et al. 2009, Zhong et al. 2007) using the Atherosclerosis Risk In 
Communities (ARIC) data. Initially, the group was able to evaluate PGE2 and IL-1 in 
GCF samples. Subsequent studies compared the relationships between the various 
cytokines found in serum (e.g. IL-6) and with systemic disease (diabetes, smoking). 
The group attempted to compare these new findings with their previous GCF results. 
The results published so far have not reported any correlations between serum and GCF 
cytokine levels. 
 
On a further note, it would be valuable to assess the 5,809 subjects enrolled in the 
ARIC population to determine correlations between various serum and GCF cytokines. 
These data would confirm or deny the current results. It is clear that new methods to 
analyse GCF cytokines are required. Tests which require less fluid volume will allow 
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multiple analyses from the one sample and would significantly improve the depth of 
our knowledge in this area. 
 
Statistical analysis 
As there has been no previous study reporting the correlation between serum and GCF 
IL-6 and TNF-α cytokine levels, sample size calculation was difficult to conduct. 
Hence, the present study was designed to be a pilot study to provide some initial data 
for future studies. The majority of studies comparing antibody levels between serum 
and GCF had approximately 20 subjects (Smith et al. 1985, Tew et al. 1985) which was 
used to guide the required number of subjects in the present study. The previous studies 
aimed to correlate the serum and GCF but did not report whether the respective levels 
were in agreement.  
 
In the current study an arbitrary value (detection limit/√2) was given for samples below 
the ELISA detection threshold rather than recording as zero. Importantly, the lack of 
detection does not imply the absence of the cytokine, rather, that it is below the 
detection limit of the ELISA assay. Eliminating these sites from statistical analysis 
would be incorrect. For example, if a cytokine was detected in serum but not in GCF it 
raises the possibility that the cytokine is degraded or bound and thus, there is a poor 
correlation between serum and GCF. In contrast, cytokine detection in both serum and 
GCF suggests a better correlation. Furthermore, excluding samples below detection 
threshold would bias the results as data would be gathered from subjects with a good 
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correlation. The investigation of the serum to GCF relationship was the focus of this 
study and therefore, samples could not be excluded if they were below detection 
threshold.  
 
The use of the Bland-Altman analysis in dentistry is not common. Previous studies 
have used the analysis to compare radiographic measurement techniques and caries 
detection devices (Howe 2009, Kamburoglu et al. 2009, Kerner et al. 2007, Kuhnisch et 
al. 2007). In medicine, it has been used to assess the agreement between devices used to 
measure blood pressure such as comparing manual or electronic sphygmomanometers. 
In this scenario, it was important that the values are not only correlated but also agree. 
The information provided by the Bland-Altman analysis can also be used to calibrate 
measurement devices. Similarly, in the current study, it was important to determine 
whether the serum and GCF cytokine levels were in agreement. Unfortunately, the low 
sample size precluded the calculation of a conversion factor to quantify the difference. 
Despite this, the current pilot study showed that agreement was poor. Therefore, until a 
larger study is completed, the collection of both GCF and serum should be considered 
when evaluating the interaction between the periodontal tissue and systemic health.  
 
Subject recruitment 
Subjects were recruited from a referral-based hospital clinic which aims to manage the 
effects of obesity and to assist weight loss. Due to the nature of this clinic most patients 
have multiple co-morbidities and were on multiple medications. As mentioned 
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previously, the intra-individual comparison allowed these co-morbidities to have less of 
an impact. Despite this, there may be mechanisms which alter relative levels of 
cytokine in serum and GCF which are not yet described.  
 
Osteoarthritis was a common condition in the present subject group. Excess body 
weight increases the loading on joints resulting in breakdown and eventual loss of 
cartilage. Currently, there are no reports on the association of osteoarthritis with 
periodontitis. In contrast, rheumatoid arthritis has an immunological basis and recent 
studies have highlighted some common findings between periodontitis and rheumatoid 
arthritis (Bozkurt et al. 2000, Dissick et al. 2010, Mercado et al. 2000). Therefore, 
subjects with rheumatoid arthritis were excluded from the current study.  
 
Apart from osteoarthritis, obstructive sleep apnoea (OSA) was also highly prevalent 
among the subjects recruited for the current study. A recent study reported a higher 
prevalence of periodontitis in patients with OSA (Gunaratnam et al. 2009). It should be 
noted, however, that many subjects who suffer from OSA are obese. Therefore, the 
relationship between periodontitis and OSA may be partly due to the subjects‟ BMI. 
The mechanism involved in linking OSA with periodontitis is thought to be due to 
increased pro-inflammatory cytokines. The effect of OSA and osteoarthritis in the 
current study was reduced by limiting the comparison of GCF and serum samples 
within each individual. 
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Excluded samples and laboratory error 
Due to research budget limitations the initial study design was modified to only 
evaluate the correlation between serum and GCF from healthy sites. The first 10 
samples were processed as a pilot investigation to confirm the presence of IL-6 and 
TNF-α in GCF and serum. The ELISA kit used to process this first run had insufficient 
quantities of reagents. The reagents became frothed following mixing which reduced 
the reagent volume. As a result the samples were reprocessed with a new kit. The 
limited GCF sample volume meant that the cytokines had to be eluted once again from 
the filter paper. Upon analysis and correction for dilution, these values were different 
from the remaining 26 samples. It was decided to exclude these initial 10 samples.  
 
The initial pilot investigation included four healthy GCF samples from a portion of the 
subjects. The initial pilot result suggested that the variation between healthy sites was 
minimal within an individual. Therefore, the protocol was modified to include samples 
from two healthy sites from each subject. In addition, the pilot investigation included 
samples from sites with BOP. Analysis revealed minimal difference between the GCF 
samples from healthy or gingivitis sites. Therefore, additional funding was sought to 
extend the protocol to test healthy and gingivitis sites within each subject. The findings 
from the initial pilot investigation were confirmed in the samples from remaining 26 
subjects. The final analysis showed minimal difference in the absorbance readings 
between the clinically similar sites within each subject which were subsequently 
pooled. Moreover, the mean amounts of cytokines collected from healthy and gingivitis 
GCF samples were not significantly different. 
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 The mean levels of cytokines evaluated in the current study should not be compared 
with those reported previously. In the current investigation, the standard solution 
required dilution because of the low levels of cytokines expected in the GCF. The 
standard curve was constructed using known values provided by the manufacturer for 
each individual plate. Unfortunately, the standard curve did not obey the Beer-Lambert 
law (Commoner & Lipkin 1949) for the range of cytokines detected in this study. 
Because of this, some readings were taken from the non-linear sections of the standard 
curve and therefore, it may not be accurate. The impact of this on the results of this 
study is not clear because there is no published data on the serum and GCF correlations 
in an obese population.  
 
The GCF and serum samples for each subject were processed on the same ELISA plate 
and this would limit the impact of a non-linear standard curve. The relativity between 
serum and GCF may still be accurate and therefore, the relative serum and GCF values 
were analysed with the Bland-Altman analysis. Consequently, the lack of agreement 
remains relevant but the actual difference between the serum and GCF cytokines is not 
known. This is an area for future research. The limitations which were encountered in 
this pilot study should be taken into consideration. 
 
Cytokine detection protocol  
The results of this study should be interpreted with the research methods in mind. GCF 
sampling is technique sensitive and the results can be influenced by many variables. 
115 
 
These include the duration of sample collection (Curtis et al. 1988) and the sample 
location within the gingival sulcus (Egelberg & Attström 1973). The most variable 
component is the method of data presentation (Lamster et al. 1988). Techniques which 
quantify the GCF volume to calculate a concentration are prone to error. Evaporation of 
the fluid is likely to result in increased concentrations. In contrast, oversaturation of the 
filter paper as a result of prolonged sampling duration can dilute the sample. Most 
significantly, when measuring GCF volume it should be remembered that gingival 
inflammation increases fluid flow and can therefore, dilute the sample (Daneshmand & 
Wade 1976, Egelberg & Attström 1973, Lamster et al. 1986). For this reason the 
current protocol was developed to record the amount of cytokine collected within a 30 
second period. While it may have inherent limitations, previous reports have shown it 
to provide the most consistent data (Lamster et al. 1988). This method of data 
presentation was suitable considering our aim and is discussed below.  
 
In the current study the concentration of cytokine in serum was compared with the 
amount present in GCF during a 30 second sampling time. This was considered an 
appropriate method to determine whether increased serum cytokines levels result in 
greater levels reaching the gingival tissue or the sulcus. The amount of cytokine per 
sample time was shown to have stronger correlations than when concentration is 
calculated using fluid volume (Engebretson et al. 1999, Lamster et al. 1988).  
 
The limitation in using this method of data presentation is that the data from serum and 
GCF samples have different units. Normally, if two fluids are to be correlated it is 
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expected that both have the same measurement unit. However, because GCF is used as 
surrogate marker to measure the amount of cytokine reaching the gingival tissue, the 
method used in this study may be adequate. Alternatively, protocols which measure 
fluid volume need to consider the possibility of sample fluid evaporation and the 
variation caused by local inflammation. The hypothesis of the present study might be 
interpreted to suggest that higher serum concentrations will lead to greater amounts of 
cytokine found within the gingival tissue as measured in GCF samples. 
 
Apart from the variability in sample collection; the results might be altered by the 
timing or conditions of sample storage and processing. Practicality is an important 
consideration when research protocols are developed. For example, it is easier to store 
samples directly after collection rather than having to process the sample prior to 
storage. Most studies process research samples in larges batches to limit laboratory 
workload. In contrast, some studies elute the cytokine immediately after collection and 
then store at -20
o
C for 48 hours until ELISA processing (Engebretson et al. 2007). 
Whether these variables influence the outcomes of the various studies is not known and 
again highlights some of the problems associated with GCF analysis. 
 
The current investigation used the filter paper method of GCF collection. In the absence 
of data suggesting a superior technique, the filter paper method was chosen because the 
cytokines in this study have been successfully recovered by various research groups 
(Boström et al. 1999, Engebretson et al. 2004, Giannopoulou et al. 2003, Khosravi et al. 
2009, Lundin et al. 2004). The number of samples below detection threshold may result 
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from the lack of GCF production at healthy sites (Miyasato et al. 1977) or alternatively, 
due to the short half life of cytokines. In addition, the elution process may not have 
removed all cytokines from the filter paper (Griffiths et al. 1988, Johnson et al. 1999). 
The magnitudes of these effects have not been quantified in previous studies and may 
be an area for future research. 
 
The contents of GCF are biological mediators and thus, likely to have a short half life. 
Degradation by enzymes or receptor blocking may represent another mechanism which 
reduces the detection rate. These processes may occur differently in blood when 
compared with GCF and the impact of this has not been quantified. The protein 
structure of cytokines may alter with time and may affect receptor-substrate binding. 
The development of newer techniques not dependent on receptors may help to 
overcome this issue. 
 
As discussed earlier, many reports described correlations between serum and GCF for 
different types of cytokines. A negative correlation between the levels of leptin in 
serum and GCF samples was found (Karthikeyan & Pradeep 2007). Engebretson et al. 
(2007) reported that plasma TNF-α correlated to GCF IL-1 but using baseline data from 
their earlier study (Engebretson et al. 2004). The limited GCF volume explains why 
they did not correlate serum TNF-α to that in GCF because the GCF samples have 
already been processed.  
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Zhong et al. (2007) collected GCF from 16 predetermined sites from 6,277 subjects 
participating in the ARIC study. The GCF was analysed using ELISA and the values 
were pooled to give a subject mean. The levels of IL-1β and PGE2 were higher in obese 
subjects. Although their GCF collection methods differed from the current study it 
would be interesting to re-analyse their data and test the presence of a correlation 
between serum and GCF cytokine in the obese subset participating in their study. This 
would expand the results of the current study and confirm whether additional cytokine 
families are poorly correlated and lack agreement. 
 
The limited volume of GCF creates difficulties in the assessment of multiple cytokines. 
Therefore, previous studies have focussed on the most relevant cytokines related to the 
condition which they are examining (Andriankaja et al. 2009, Engebretson et al. 2004). 
Similarly, in the current study IL-6 and TNF-α were chosen because of their 
relationship to obesity, periodontitis and diabetes. Subsequent research may identify 
other molecules which could have been investigated in the current study but were not 
possible due to the lack of GCF volume. 
 
Detection of IL-6 and TNF-α in serum were reported in previous studies (Buhlin et al. 
2003, Furugen et al. 2008), however, the levels were quite variable. The mean value in 
the current study was much greater than that reported in the above studies. This may 
relate to differences in subject selection (i.e. the subjects BMI) or differences in 
laboratory assay and standard curve construction. These studies failed to show any 
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difference in serum IL-6 and TNF-α between those with periodontitis and those 
without.  
 
Similar to the results of the current study, Giannopoulou et al. (2003) showed that the 
mean levels of IL-6 in GCF were not different between healthy and gingivitis sites in 
smokers. Along with the current study, the results suggested that in certain sub-groups 
(smokers and the obese) that the impact of local inflammatory mediator production is 
minimal compared with the amount arising from a systemic source. Therefore, future 
studies are required to expand on this new finding.  
 
Our results revealed a high detection rate of serum IL-6 which was likely due to the 
obese and/or diabetic subject selection. Loos (2005) suggested that IL-6 might only be 
detected in up to 53% and 42% of serum samples from periodontitis and healthy 
subjects, respectively. The low serum levels may result in a low rate of detection in 
GCF unless they are produced locally. In contrast, our study showed that even with 
high levels of IL-6 in serum, the levels were not always correspondingly high in GCF 
samples from healthy gingival sites.  
 
The median amount of IL-6 in the GCF from gingivitis sites was not significantly 
different from the healthy sites. This suggested that the local inflammatory response in 
an inflamed gingival site is not elevated due to higher serum levels of these cytokines. 
This would question the biological relevance of raised pro-inflammatory cytokines in 
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serum arising from adipose tissue. However, our data did not include periodontitis sites 
which would have strengthened this unexpected finding. Interestingly, this might also 
suggest that higher background levels of cytokines may be present in the GCF from 
healthy sites of obese subjects. Whether this higher background level translates into 
increased risk for periodontitis or gingivitis is unknown and requires further evaluation. 
 
Gorska et al. (2003) investigated the correlation between serum and gingival biopsy 
concentrations of various cytokines. Two groups of medically healthy subjects were 
examined; a periodontitis group and a control group undergoing adult orthodontic 
treatment. The study showed TNF-α was not detected in 50% of serum samples. These 
results suggested that the highly variable levels of serum cytokines did not correlate 
with clinical variables. In relation to the current study, Gorska et al. (2003) did not 
correlate the levels of cytokines in serum to those found in the gingival biopsy samples. 
The variable levels of cytokines in the gingival tissue may reflect differences in serum, 
however, this remains untested. 
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7. SUMMARY AND CONCLUSION 
The results of the present study suggest that, in obese subjects, the levels of TNF-α in 
serum are not well correlated to the levels in GCF from healthy and gingivitis sites. In 
comparison, IL-6 showed statistically significant correlations between samples taken 
from serum and the GCF of both healthy and gingivitis sites. The high correlation 
between serum and GCF samples from gingivitis sites might indicate that higher serum 
IL-6 levels leads to increased amounts of IL-6 released into the GCF. Alternatively, 
increasing GCF levels of IL-6, in the presence of gingival inflammation, might lead to 
higher levels of IL-6 in serum. 
 
Future studies examining the effect of systemic cytokines on the periodontium should 
consider evaluating both serum and GCF. This would allow differentiation of the 
cytokines arising from serum versus those produced locally. It will also help to 
determine if the cytokines present in the serum remain at sufficient levels to have an 
impact on the gingival tissue. 
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8. APPENDIX 
8.1 Recruitment letter 
Correlation of adipokines in serum and gingival crevicular fluid of obese patients 
with and without periodontitis. 
 
Dear....,  
 
The Westmead Centre for Oral Health is conducting a research project on gum disease. 
This study will be conducted in association with Dr Jonathan Marks, Director 
Westmead Hospital Obesity Clinic. You have been invited to participate in the study 
because you have attended the Obesity Clinic in Westmead Hospital. The overweight 
population has been targeted because they appear to have an increased risk of 
developing severe gum disease. 
 
The study will involve a dental examination. In addition, a saliva and a blood sample 
will be collected. This treatment will usually involve one appointment only of 
approximately 60 minutes duration. This study has been approved by the Sydney West 
Area Health Service ethics committee; reference number HREC2009/2/4.6 (2920). 
 
The benefit of participating in this research will be that you will receive a thorough 
dental examination and oral hygiene instruction. This examination will identify 
treatment you require. If you are eligible for public dental treatment, you will be 
offered an appointment for tooth cleaning and then placed on the waiting list to assess 
for further dental treatment.  
 
To participate in the study it is important that you do not have a heart murmur, do not 
smoke and have not taken antibiotics in the last three months. If you are diabetic, it 
must be well controlled for you to be included in the study (HbA1c <8%). 
 
If you are interested in a free dental examination and are willing to participate in this 
study please contact the study co-ordinator Dr Robert Fell, on (02) 9845-5951. If you 
leave a message, please identify yourself as a research patient and Dr Fell will call you 
back to discuss any questions you may have. 
 
Thank you for your attention. 
 
Kind Regards,  
 
 
Dr Robert Fell 
BDS (Hons) FRACDS 
Periodontics Registrar 
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8.2 Participant information form 
What is the purpose of the study?  
 
We are investigating whether hormones released into the blood from fat cells influence 
the health of the gums (Periodontitis). These hormones (inflammatory mediators) have 
been linked to many diseases, including coronary heart disease. Studies have shown 
than an association exists between obesity and periodontitis (gum disease). To study 
this relationship we will need to collect a blood sample and compare it to the contents 
of your saliva fluid.  
 
Who will be invited to enter the study?  
 
You have been invited to enter the study because you are patient who has attended 
Westmead hospital and have shown interest in losing weight. You may also have gum 
disease (chronic periodontitis) and be attending either the undergraduate or 
postgraduate clinics at the Westmead Centre for Oral Health, Westmead Hospital. 
 
What will happen on the study?  
A medical history will be taken and a screening dental examination will be carried out. 
This will determine the presence of gum (periodontal) disease.  
 
The sequence of events to be conducted is as follows  
We will ask you to sign a consent form once you are fully informed of the study 
procedures and after any questions you may have are answered.  
We will ask questions to determine your status of general health and wellbeing. 
We will assess the state of the gums. 
We will take a saliva sample from your mouth.  
We will take a blood sample with a needle from a vein in your arm.  
 
We will ensure that you experience a minimum amount of discomfort during or after 
the appointment.  
 
The procedures performed within your mouth will be the same as those encountered 
during the course of a routine dental check-up. We will look at the result of your blood 
test to assess the hormone (inflammatory mediators), sugar and cholesterol levels. We 
will NOT perform any unrelated tests such as blood cell counts, HIV or Hepatitis tests.  
 
During the appointment, we will take blood samples from a vein in your arm using a 
small needle. This procedure is identical to a standard blood test which your medical 
doctor may have arranged for you in the past. We will need to take one blood sample 
during the first appointment. You will have given 20ml of blood, which is less than 
10% of the blood volume that blood donors give each time they donate to the Red 
Cross or one (1) tablespoon of blood. All blood samples will be taken with a sterile 
needle. 
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Are there any risks? 
 
All medical procedures involve some risk of injury. In addition, there may be risks 
associated with this study that are presently unknown or unforeseeable. In spite of all 
reasonable precautions, you might develop medical complications from participating in 
this study. There is an estimated risk of less than 5% of infection or bruising at the 
needle site. You may also feel a slight prick as the needle is inserted.  
 
Are there any benefits?   
 
As a participant in this study, you will have all your gum treatment needs identified. If 
you are eligible for public care you will be offered free treatment. 
 
Confidentiality / Privacy  
 
All aspects of this study, including results, will be strictly confidential and only the 
researchers will have access to your personal information. Any publication of the 
results from this study will use only de-identified information. Your patient 
confidentiality will be preserved at all times.  
 
Do you have a choice?  
 
Your participation in this study is entirety voluntary. If you choose not to join the study 
or you wish to withdraw from it at any time during or after the appointment, we shall of 
course immediately stop your participation in the study. Your participation or non-
participation in this study will not affect your dental care in any way.  
 
Complaints  
 
If you have any concerns about the conduct of the study, or your rights as a study 
participant, you may contact:  
Westmead Hospital Patient Representative, Ms Jillian Gwynne Lewis,  
Telephone No 9845 7014 or email jillian.lewis@swahs.health.nsw.gov.au 
 
If you are a staff member then the contact person for your complaint is:   
The Secretary, SWAHS Human Research Ethics Committee  
Telephone No 98458183 or email researchoffice@wmi.usyd.edu.au  
 
Results  
 
If you wish to be advised of the results of this study upon its conclusion then you may 
contact Dr. Robert Fell, whose contact details are listed below and he will forward a 
summary sheet of the findings on to you.    
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8.3 Consent form 
1. I understand that the researcher will conduct this study in a manner conforming 
with ethical and scientific principles set out by the National Health and Medical 
Research Council of Australia and the Good Clinical Research Practice Guidelines of 
the Therapeutic Goods Administration.  
2. I acknowledge that I have read, or have had read to me, the Participant 
Information Sheet relating to this study. I acknowledge that I understand the Participant 
Information Sheet. I acknowledge that the general purposes, methods, demands and 
possible risks and inconveniences which may occur to me during the study have been 
explained to me by Dr Robert Fell (“the researcher”) and I, being over the age of 18 
years, acknowledge that I understand the general purposes, methods, demands and 
possible risks and inconveniences which may occur during the study.  
3. I acknowledge that I have been given time to consider the information and to 
seek other advice.  
4. I acknowledge that refusal to take part in this study will not affect the usual 
treatment of my condition.  
5. I acknowledge that I am volunteering to take part in this study and I may 
withdraw at any time.  
6. I acknowledge that this research has been approved by the Sydney West Area 
Health Service Human Research Ethics Committee. 
7. I acknowledge that I have received a copy of this form and the Participant 
information Sheet, which I have signed.  
8. I acknowledge that any regulatory authorities may have access to my medical 
records to monitor the research in which I am agreeing to participate. However, I 
understand my identity will not be disclosed to anyone else or in publications or 
presentations.  
 
Before signing, please read „IMPORTANT NOTE‟ following.  
 
Name of participant ____________________________ Date of Birth ______________                                 
 
Address of participant ____________________________________________________                                
 
Signature of participant _________________________Date:  ____________________ 
 
Signature of researcher _________________________ Date:  ___________________ 
 
Signature of witness____________________________ Date: ____________________          
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IMPORTANT NOTE 
1. Where a participant is over the age of 18 years, then by the participant 
personally.  
2. Where a participant is under a legal or intellectual disability, e.g. unconscious, 
then particular consent should be sought from the Human Research Ethics Committee 
as to whether the person should take part in the research.  
 
WITNESS:  
 
I,                                                                                                                  (name of 
witness)  
 
of ________________________________________________   hereby certify as 
follows: 
 
1. I was present when _____________________________ („the participant”) 
appeared to read or had read to him/her a document entitled Participant Information 
Sheet; or I was told by ___________________________________ (“the participant”) 
that he/she had read a document entitled Participant Information Sheet (Delete as 
applicable) 
 
2. I was present when ¬¬¬¬¬¬___________________________ („the researcher”) 
explained the general purposes, methods, demands and the possible risks and 
inconveniences of participating in the study to the participant. I asked the participant 
whether he/she had understood the Participant Information Sheet and understood what 
he/she had been told and he/she told me that he/she did understand.   
 
3. I observed the participant sign the consent to participate in research and he/she 
appeared to me to be signing the document freely and without duress.  
 
4. The participant showed me a form of identification which satisfied me as to 
his/her identity.  
 
5. I am not involved in any way as a researcher in this project. 
 
6. (Delete this clause if not applicable) I was present when 
_______________________ 
(“the interpreter”) read the Participant Information sheet to the participant in the 
__________________(here insert appropriate language) language. I certify that when 
the researcher explained the general purposes, methods, demands and possible risks and 
inconveniences of participating in the study that what was said by both the researcher 
and the participant was translated by the interpreter from the English language into the 
above language and vice versa. When I spoke to the participant what I said and what 
the participant said was translated by the interpreter from the English language into the 
above language and vice versa.  
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Name of witness ________________________________________________________ 
 
Address _______________________________________________________________ 
 
Signature of Witness _____________________________________ Date: __________ 
 
Relationship to participant ________________________________________________ 
 
 
 
INTERPRETER:  
 
If an interpreter is used, the following addition is necessary: 
 
I ___________________________________________________ (name of interpreter) 
 
of ____________________________________________________certify as follows: 
 
1. I am qualified to translate speech and writing from the English language into the 
___________________ language and vice versa.  
 
2. I read the Participant Information Sheet to the participant in the above language 
and he/she appeared to understand it.  
 
3. I was present when the researcher explained the general purposes, methods, 
demands and possible risks and inconveniences of participating in the study to the 
participant and I translated all that was said by the researcher and by the participant 
from the English language into the above language and vice versa.   
 
4. I was present when the independent witness spoke to the participant and I 
translated all that was said by the witness and by the participant from the English 
language into the above language and vice versa.  
 
 
  
Signature of Interpreter _________________________________Date _____________ 
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8.4 Questionnaire 
Correlation of adipokines in serum and gingival crevicular fluid of obese patients with 
and without periodontitis. 
 
Name 
Gender  
Age  
 
Thank you for your participation in this study. Please answer the following questions. If 
you are unsure about the answers to any questions then please let Dr. Fell know and he 
will clarify the question for you.  
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8.5 Data collection form 
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